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This dissertation is a compilation of the work we have done in the past five years using 
fast-scan cyclic voltammetry in model organisms to solve biological problems. In this work, we 
use fast-scan cyclic voltammetry to measure neurotransmitter release in rodent models of 
neurodegeneration and neurotoxicity. Later, we develop this technique for use in zebrafish whole 
mount retinas. 
In Chapter One, we will introduce fast-scan cyclic voltammetry and the underlying 
electrochemical concepts. We will also introduce the various biological problems investigated in 
this work and the model organisms used to investigate these problems.  
In Chapter Two, we will discuss fast-scan cyclic voltammetry measurements of serotonin 
release in Huntington’s disease model mice. We have demonstrated that serotonin release is 
impaired in multiple regions of the brain and across multiple mouse models.  
In Chapter Three, we will discuss fast-scan cyclic voltammetric measurements of both 
dopamine and serotonin in chemotherapy-treated rats. Here, we have treated rats with both 
carboplatin and 5-fluorouracil in order to investigate the effect of chemotherapy on 
neurotransmitter release. Additionally, we will discuss our collaboration with Dr. David 
Jarmolowicz, in which his lab measured cognitive behavioral changes in rats treated with 
chemotherapy. We have also investigated the novel drug, KU-32, developed by Dr. Brian 
Blagg’s group, as a potential therapy for chemotherapy-induced cognitive changes. 
In Chapter Four, we will discuss our work developing a method to measure light-
stimulated neurotransmitter release in adult zebrafish whole mount retinas. Here, we have shown 




through pharmacological studies that dopamine can be measured using fast-scan cyclic 
voltammetry in the retina. 
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For this work, we obtained measurements of neurotransmitter release and uptake using 
fast-scan cyclic voltammetry at carbon fiber microelectrodes. This technique has several 
advantages. The 7 µm diameter of the carbon fiber electrodes allows for high spatial resolution 
and also minimizes tissue damage. Additionally, the fast scan rate combined with background 
subtraction provides sub-second temporal resolution. Also, this technique gives limits of 
detection in the nM range, which is suitable for the concentrations of neurotransmitters released 
in the brain. Finally, fast-scan cyclic voltammetry has a good specificity, which allows for 
identification of the analyte of interest without a separation step.  
 
1.2 ELECTROCHEMICAL CELLS 
This work relies on fast-scan cyclic voltammetry (FSCV), an electrochemical technique, to 
quantify changes in neurotransmitter concentrations in biological tissues. Therefore, it is 
important to discuss the fundamentals of electrochemical analysis. The foundation of 
electrochemical techniques lies in electrochemical cells. A galvanic cell contains a 
spontaneously-occurring reaction at electrodes that generates a current when connected by a salt 
bridge. On the other hand, an electrolytic cell requires an external power source and can push 
nonspontaneous reactions to occur at electrodes. Figure 1.2.1 shows a galvanic cell .
1
 





Figure 1.2.1. Schematic diagram of a Galvanic cell. 
In this work, a two-electrode cell is used to make electrochemical measurements. Two-
electrode cells typically consist of a working electrode and reference electrode, while a three-
electrode cell includes a counter electrode in addition to the other two. Here, we will discuss the 
components of the two-electrode cell used.  
The working electrode is the electrode at which the reaction of interest occurs; in this 
work, a carbon fiber microelectrode is used. The reference electrode is an electrode whose 
behavior approaches that of an ideal nonpolarizable electrode. Figure 1.2.2 shows current 
potential curves for an ideal polarizable electrode (left) and an ideal nonpolarizable electrode 






 Ideal nonpolarizable electrodes make good reference electrodes because their potential 
remains constant regardless of changes in current.
1
 Although actual electrodes never behave 
exactly as ideal ones, in this work, an Ag/AgCl electrode was used as a reference, and 
approximates an ideal nonpolarizable electrode under the experimental conditions. 
 




Under conditions in which measurements are obtained in highly resistive solutions or when large 
currents are measured, a three-electrode cell may be required, in which current passes between 
the counter and working electrodes. In this type of cell, a counter electrode is required to correct 
for IR drop, which is the decrease in applied potential at the electrode surface.
2
 In this work, a 
two-electrode cell is used. Due to the use of carbon fiber microelectrodes, currents measured are 
on the order of nanoamps; thus, the currents at the working electrodes are sufficiently low to 
avoid a significant ohmic drop, and a counter electrode is not necessary.
2
 Figure 1.2.3 shows a 
schematic of a two-electrode cell. 





Figure 1.2.3. A schematic showing a two-electrode cell. 
1.2.1 Faradaic current and electrode reactions 
Faradaic current is electron flow due to an oxidation or reduction reaction. For a Faradaic 
process, the amount of current will be directly proportional to the charge transfer in an oxidation 
or reduction reaction.
2
 For electroanalytical chemistry, this is important since it means that an 
electroactive analyte can be quantified by the oxidation or reduction current generated when a 
potential is applied. For a redox reaction producing faradaic current, the following equations are 
relevant: 
      
  
  




Where Q = charge, n = moles of analyte, F is faraday’s constant, N is the number of electrons in 
the redox reaction, i is current, and t is time. Thus, faradaic current is equal to charge transfer 
over time and is proportional to the moles of analyte.
3
 Figure 1.2.4 shows a schematic of a 
Faradaic process: the oxidation of A to A
+
 at an electrode surface. As the potential of the 




electrode becomes more positive, the energy level of the electrons at the electrode surface 
becomes lower than the species A’s highest occupied molecular orbital. When this occurs, 







Figure 1.2.4. Oxidation of A to A
+
. 
1.2.2 Capacitance at the electrode-solution interface 
A capacitor is any two conductive materials in proximity to each other, with a separation 
such that charges cannot cross, and across which charge can be stored. Thus, the electrode-
solution interface can be thought of as a capacitor, of sorts, because charges cannot cross. 





Where C is capacitance, q is the charge stored, and E is the potential across the capacitor.
1
 
Figure 1.2.5 shows (A) a capacitor in a circuit, and (B) the interface of a negatively charged 
electrode in solution as a capacitor. Capacitance is important in the context of our measurements 




using fast-scan cyclic voltammetry because of the significant capacitive charging current that 
occurs at high scan rates. 
 
Figure 1.2.5. (A) A capacitor as part of a circuit. (B) An electrode with a negatively charged 
surface as a capacitor in solution. 
An electric double-layer forms at electrode surfaces due to charge separation across the 
solution-electrode interface. Figure 1.2.6 shows a schematic of the electric double-layer. Here, 
anions are specifically adsorbed to the surface of the electrode. Represented by x1 is the locus of 
electrical centers of specifically adsorbed ions. Due to the specific adsorption of anions here, 
solvated cations can only approach the electrode surface to the distance represented by x2. The 
solvated cations here are nonspecifically adsorbed.
1
  





Figure 1.2.6. The electric double-layer.  
1.3 VOLTAMMETRY 
In this work, voltammetry is used to measure transient changes in neurotransmitter 
concentrations in biological tissues. Voltammetry is a group of electrochemical techniques in 
which a known potential is applied at a working electrode, and the resulting current from any 
reactions occurring at the electrode is measured.
2
 These techniques include square wave 
voltammetry and various potential step methods. This work makes use of cyclic voltammetry, a 
linear sweep method in which the potential is increased from a given holding potential at a 
selected scan rate. In these experiments, potential E is a function of the scan rate v and time, t: 
     




After the switching potential is reached, the scan rate switches from v to -v, and the potential 
returns to the holding potential until the waveform is scanned again.
4
 Figure 1.3.1 shows a 
typical waveform used for cyclic voltammetry. In cyclic voltammetry at macroelectrodes, scan 
rates are typically on the order of 100-1000 mV. 
1 .0  V
-0 .4  V -0 .4  V
 
Figure 1.3.1. A typical waveform used for cyclic voltammetry. 
 As the potential is scanned up from negative to positive, oxidation of the analyte of 
interest can occur at the electrode surface, resulting in faradaic current. The oxidation and 
reduction currents can be plotted vs. potential in order to obtain a cyclic voltammogram, which 
serves as a signature of a given analyte. What happens on the reverse scan is determined by the 
type of reaction: reversible, quasi-reversible, irreversible, or chemically irreversible. In a 
reversible reaction, the difference between oxidation and reduction potentials is less than 0.058 
V/n, where n is the number of electrons transferred; a reversible reaction will obey the Nernst 
equation:  
       
  
  
    
    
     
) 
Where E is applied potential, E
0
 is the formal reduction potential of the analyte, R is the 
universal gas constant, n is the number of electrons transferred in the reaction, and F is Faraday’s 




constant. The Nernst equation describes the changes in concentrations of species due to oxidation 
and reduction at the electrode surface as a function of applied potential, where    is the formal 
reduction potential of the analyte, R is the universal gas constant, n is the number of electrons 
per reaction, and F is the faraday constant.
1
   
For a quasi-reversible reaction, the separation between oxidation and reduction peaks will 
exceed 0.058 V/n, and irreversible reactions will have a peak separation of far greater than 0.058 
V/n. In the case of a chemically irreversible reaction, a molecule oxidized at the electrode 
surface will undergo a chemical change preventing a reduction reaction on the reverse scan.
1
 In 
this work, significant non-faradaic charging currents are generated at the working electrode. 
Figure 1.3.2A shows a typical potential-versus-time plot for a linear sweep experiment, where 
potential is ramped up over time. As potential is ramped up, resulting non-faradaic charging 
current reaches a steady state.
1
 Here, the charging current is given by the scan rate and 
capacitance of the double-layer. Figure 1.3.2B shows plots for a triangular waveform, where 
potential is ramped up to a switching potential, and then back down. In this case, the steady state 









Figure 1.3.2. (A) Resultant charging current in a potential sweep experiment. (B) Applied 
potential (top), resulting charging current versus time (middle), and resulting charging current 
versus potential (bottom) in a cyclic voltammetry experiment. Figure adapted from Bard and 
Faulkner, with permission. ©John Wiley and Sons (2000). 




1.4 FAST-SCAN CYCLIC VOLTAMMETRY 
1.4.1 Introduction to fast-scan cyclic voltammetry 
This work makes use of techniques originally developed here, at the University of 
Kansas, by Ralph N. Adams. In 1958, Adams first published on his invention of carbon paste 
electrodes,
5
 which were a major innovation over the mercury electrodes that were dominant in 
electroanalytical chemistry at the time.
6
 Then, in 1967, Adams published on oxidation reactions 
of catecholamines,
7
 and followed this six years later with in vivo voltammetric measurements 
using carbon paste electrodes.
8
 Adams’s work laid the foundation for the development of 
voltammetry as a technique to measure catecholamines in biological tissues. In this work, cyclic 
voltammetry is used in the central nervous system to measure neurotransmitter release. As 
discussed in section 1.3, cyclic voltammetry is a linear sweep method in which a potential is 
ramped up to some switching potential, and then back down to the holding potential at some scan 
rate. In fast-scan cyclic voltammetry, scan rates of up to 10
5
 V/s have been used.
9
 The fast scan 
rate allows for increased sensitivity and the ability to detect rapid changes in analyte 
concentration.
9
 As discussed in section 1.3, experiments involving a linear potential sweep 
generate charging currents proportional to the potential scan rate. In this work, scan rates range 
from 300 V/s to 800 V/s; therefore, large charging currents are generated, and it is necessary to 
use background subtraction to obtain useful data. Figure 1.4.1 shows an example of a 
background-subtracted cyclic voltammogram for dopamine. In this process, multiple cyclic 
voltammograms are averaged over time. This averaged background cyclic voltammogram is then 
subtracted from the other cyclic voltammograms throughout a given file obtained, in order to 
yield a background-subtracted cyclic voltammogram. This does create a limitation: fast-scan 
cyclic voltammetry cannot detect absolute concentrations; it can only detect changes in 




concentration. However, since we are interested in measuring neurotransmitter release in 
response to stimuli and not endogenous concentrations, this limitation falls outside the scope of 
this work. 
-0 .4 V + 1 .0 V
-2 0 0 0 n A
+ 2 0 0 0 n A
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Figure 1.4.1. Fast-scan cyclic voltammetry is a background-subtracted technique.  
1.4.2 Carbon fiber microelectrodes 
In this work, carbon fiber microelectrodes were used with fast-scan cyclic voltammetry to 
obtain neurotransmitter release measurements in biological tissues. When used with fast-scan 
cyclic voltammetry, the small size of carbon fiber microelectrodes allows low limits of detection, 
high temporal resolution, and high spatial resolution.
9
 Electrode fabrication will be discussed in 
greater detail in the Methods sections of later chapters, but a brief introduction will be given 
here. The electrodes were made in-house, consisting of 7 µM diameter carbon fiber, cut to 30 
µM in length, and encased in a glass sheath.  Figure 1.4.2 shows a scanning-electron microscopy 
image of a carbon fiber microelectrode. 





Figure 1.4.2. Scanning electron microscope image of a carbon fiber microelectrode tip.  
1.4.3 Voltammetry of Dopamine 
In this work, dopamine is measured at carbon fiber microelectrodes using fast-scan cyclic 
voltammetry. This was done using a waveform scanning up from a holding potential of -0.4 V, 
up to a switching potential of 1.0 V, and back down to -0.4 V at 300 V/s. As the potential is 
scanned from negative to positive, in a two-electron oxidation, dopamine is converted to 
dopamine-o-quinone at about 0.6 V, and an oxidation peak appears on the cyclic voltammogram. 
As the potential is scanned back down, dopamine-o-quinone is reduced back to dopamine at 
about -0.1 V, and a reduction peak appears on the cyclic voltammogram. Figure 1.4.3 shows a 
dopamine waveform along with a characteristic dopamine cyclic voltammogram and the redox 
reaction of dopamine to dopamine-o-quinone. 
 





Figure 1.4.3. Dopamine oxidation to dopamine-ortho-quinone and reduction back to dopamine 
at the electrode surface and the resulting cyclic voltammogram. 
 
1.4.4 Voltammetry of Serotonin 
The other neurotransmitter discussed at length in this work is serotonin. A serotonin-
optimized waveform
10
 was used to make serotonin measurements. This waveform consists of a 
sawtooth pattern in which potential is increased from 0.2 V up to 1.0 V, down to -0.1 V and back 
up to a holding potential of 0.2 V at 800 V/s was used. On the positive scan, serotonin is 
oxidized in a two-electron oxidation to serotonin-p-quinone imine around 0.8 V. On the reverse 
scan, serotonin-p-quinone imine is reduced back to serotonin around 0.0 V. This waveform was 
found by Hashemi et al. to be more sensitive to serotonin than dopamine by 50-fold because 
dopamine-o-quinone, the oxidation product of dopamine, is not reduced back to dopamine until -
0.1 V.
10
 Further considerations for measuring serotonin in brain slices will be discussed in 




Chapters 2 and 3 of this work. Figure 1.4.4 shows the serotonin waveform that was used, the 
serotonin redox reaction, and a characteristic serotonin cyclic voltammogram. 
  
Figure 1.4.4. Serotonin waveform, cyclic voltammogram, and oxidation to serotonin-p-quinone 
imine. 
1.4.5 Color plots 
Raw data were collected in the form of color plots, which allow for visualization of 
multiple cyclic voltammograms over time. Figure 1.4.5 shows a representative color plot 
collected in a flow cell. Here, time is plotted on the x-axis. Potential is plotted on the y-axis, and 
current is represented by false color, with the green color representing positive current, yellow 
representing currents close to zero, and dark blue representing negative current. Cyclic 
voltammograms are unfolded and stacked over time to obtain these plots. Taking a horizontal 
slice of the color plot, the current versus time plot can be viewed to determine current changes 
over time, while a vertical slice gives an extracted cyclic voltammogram collected at that specific 
time. The background can be subtracted from any time point to obtain a background-subtracted 
cyclic voltammogram.  





Figure 1.4.5. Representative color plot collected during flow cell analysis of dopamine. Cyclic 
voltammograms are unfolded, rotated such that current peaks are on the z-axis represented in 
false color, and stacked over time. 
1.5 NEUROTRANSMISSION 
The central nervous system is composed of two parts: (1) the brain, and (2) the eye. The 
central nervous system is distinct from the peripheral nervous system, which consists of other 
nerves throughout the body.
11
 The cells in each of the components of the nervous system, 
however, communicate in much the same way via action potentials.
12-15
 
Neurons are made up of three major parts: (1) the cell body, (2) the axon, and (3) the 
dendrites,
16
 as shown in Figure 1.5.1.  





Figure 1.5.1. A schematic showing the main parts of a neuron.  
Typically, a neuron receives input at the dendrites.
17-18
 If a neuron’s membrane potential 
becomes sufficiently depolarized, an action potential takes place,
15
 where an electrical current is 
propagated down the axon, and neurotransmission can occur at the terminals.
19-20
 When a neuron 
is in its resting state, its membrane potential rests at -70 mV, and voltage-gated channels remain 
closed.
21-22
 When the membrane potential is sufficiently depolarized to a threshold of -55 mV, 
voltage-gated channels open, and sodium enters the axon, which further increases the cell 
membrane potential.
23-24
 As the available sodium channels continue to open, the membrane 
potential increases to +40 mV with the rapid influx of sodium ions.
12
 The membrane potential 
reaches a maximum when the sodium channels close and potassium channels open.
24
 Then, an 
efflux of potassium from the cell occurs, hyperpolarizing the cell membrane before eventually 
returning to its resting voltage of -70 mV through active transport via sodium/potassium 
pumps.
12, 23
 This cycle of membrane depolarization and resulting electrical impulses propagates 
down an axon, ultimately triggering exocytotic release of neurotransmitters into synapses.
25
 
Release of neurotransmitters into the synaptic cleft (i.e. space where neurons contact each other) 
allows for intercellular communication.
20, 25-26
 





Dopamine is a monoamine neurotransmitter that has been implicated in many brain 




 and motor control.
29
 Moreover, dopamine 





 and Huntington’s disease.
33-42
  
1.6.1 Dopamine in the striatum 
The striatum is part of the basal ganglia, which is a group of sub-cortical nuclei located in 
the forebrain. Other components of the basal ganglia include the globus pallidus, entopeduncular 
nucleus, subthalamic nucleus, substantia nigra pars compacta, substantia nigra pars reticulata, 
and nucleus accumbens.
43
 The striatum contains both the caudate putamen and nucleus 
accumbens, both of which are heavily innervated with dopamine.
43
 The two primary pathways 
from which the striatum receives dopaminergic input are the mesolimbic pathway, via the ventral 
tegmental area, and the nigrostriatal pathway via the substantia nigra pars compacta.
44
 Figure 
1.6.1 shows a schematic diagram of the dopaminergic pathways in the adult mouse brain.
45
 The 
ventral striatum has been implicated in reward and motor function,
47
 while the dorsal striatum 
has been shown to have some role in learning. 
46
 GABAergic neurons make up 90-95% of cell 
bodies in the striatum.
48
 These cells are called “spiny” because of their dendritic projections that 
are covered in spines.
48
 Alterations in the striatum have been associated with many disease states 
and neuropsychiatric conditions, including schizophrenia,
49-51











 and Huntington’s disease.
33
  





Figure 1.6.1. Dopaminergic pathways in the adult mouse brain. Reproduced from Money KM 
and Stanwood GD (2013), Open Acess.
45
  
1.6.2 Dopamine in retina 
For a more detailed description of the retinal architecture and dopamine function in the 
retina, see Chapter 4. Briefly, dopamine in the retina is primarily located in A2 amacrine cells. 
These cells integrate and modulate visual messages to ganglion cells.
57
 Dopamine function has 







 and age-related macular degeneration.
63-64
   
1.6.3 Dopamine synthesis, release, and uptake 
Throughout this work, neurotransmitter release is evoked via electrical or light stimulus, and 
neurotransmitter release is manipulated via pharmacology. Therefore, it is important to discuss 
the synthesis, release, and uptake of dopamine at synapses. Figure 1.6.2 shows this process. 




Dopamine is synthesized from tyrosine;
65
 the rate-limiting step is the conversion of tyrosine to L-
DOPA by tyrosine hydroxylase.
66
 L-DOPA is then converted to dopamine by DOPA 
decarboxylase.
67-69
 Vesicular monoamine transporter then packages dopamine into vesicles,
70
 
which can be released into the synapse by exocytosis, where the vesicle fuses with the cell 
membrane and releases its contents into the extracellular space.
25
 Upon release, dopamine can be 
taken back into the cell by dopamine transporter,
31, 70
 bind to autoreceptors on the same neuron 
from which it was released,
71
 diffuse across the synaptic cleft and bind receptors on a different 
neuron, or diffuse out of the synaptic cleft and act on distance receptors.
20, 72
 





Figure 1.6.2. A schematic diagram showing the synthesis, release, and uptake of dopamine. 
 
1.7 SEROTONIN 









 Figure 1.7.1 shows a diagram of serotonin innervation. Serotonergic 
innervation originates in the raphe nuclei, located in the brainstem.
78
 These nuclei consist of the 
rostral nuclei, which is composed of the caudal linear nuclei, dorsal raphe nuclei, and median 




raphe nuclei, and the caudal nuclei, which is composed of the nucleus raphe magnus, the raphe 
obscurus nucleus, the raphe pallidus nucleus, and the lateral medullary reticular formation.
73
 The 





Figure 1.7.1. Serotonergic innervation originates in the raphe nuclei. The rostral nuclei and 
projects into cortical and subcortical structures, while the caudal nuclei projects into the 
brainstem. B1-B3 are the caudal nuclei and project to the spinal cord and peripheral nervous 
system. The rostral nuclei are the dorsal raphe (B6 and B7) and the median raphe (B5 and B8), 
which project into the cortical and subcortical structures. Figure reproduced from Murphy and 
Lesch, with permission. ©Nature Publishing Group (2008).
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The substantia nigra pars reticulata receives input from the dorsal raphe nucleus, where 
serotonin is synthesized. The dorsal raphe nucleus contains about 50% serotonergic neurons, and 
has the highest concentration of serotonergic neurons in the brain.
78
 The substantia nigra pars 




reticulata has been found to be involved in motor control and movement disorders,
42, 81-85
 while 
the dorsal raphe nucleus appears to be important in depression and neuroplasticity.
86-87
 In this 
work, we measured serotonin release in both the substantia nigra pars reticulata and dorsal raphe 
nucleus of rodent models.  
1.8 ANIMAL MODELS  







 This work relies on the use of rats, mice, and zebrafish to model 
neurological function. This introduction provides only a brief overview; additional details of 
each model organism used are provided in the individual chapters.  
1.8.1 Historical perspectives of model organisms in research 
Animals have been used for research for over 2400 years—at least since ancient Greece. 
In the 6
th
 century BCE, Alcmaeon of Croton used dogs to determine that the brain was the seat of 
intelligence. By the 4
th
 century BCE, Aristotle used chicks as a model for embryogenesis. 
Around a century later, Erasistratus determined that the heart functioned as a pump using animal 
models. In the 12
th
 century, Avenzoar practiced surgical techniques on animals, such as 
tracheotomies, and in the 17
th
 century, William Harvey was able to use animal models to 
describe in detail the workings of the cardiovascular system.
100
  
Within the past century, animal research has taken off to an even greater extent. With the 
advent of genetic manipulation, a new world of research possibilities in animal models was 
opened; the first transgenic mouse was developed in 1976.
101
 Figure 1.8.1 shows the rapid 







 have all been fully sequenced. In this work, each of these model 




organisms is used to shed light on neurotransmitter release. There are several considerations for 
choosing a model organism, including cost, ease of use, duration of life cycle, and relevance to 
humans. Oftentimes, this is a balancing act; invertebrates such as drosophila and Caenorhabditis 
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Figure 1.8.1. The use of animal models, especially mice, has skyrocketed since the 1970s.  
1.8.2 Rodent model organisms 
In this work, rats are used to study the effect of chemotherapy treatment on the brain. In 
Chapter 3, this will be discussed in further detail; briefly, rats were treated with 
chemotherapeutic agents via i.v. tail vein injections. Our collaborator, Dr. David Jarmolowicz, 
and his lab measured cognitive changes in rats receiving chemotherapy. At the end of a full 
course of chemotherapeutic treatments, our lab performed neurochemical analysis in the form of 
FSCV in brain slices.  Rats (rattus norvegicus) have several advantages as model organisms. Due 
to their relatively large size, administration of chemotherapy via i.v. tail vein injection is easier in 








Mice (mus musculus) are also used in this work to study changes in the brain in 
Huntington’s disease. Specifically, mutant mice carrying a truncated version of the human 
Huntington gene were used. FSCV measurements were made in brain slices of these mutant 
Huntington’s disease model mice. The major advantage to using mice is that they have proven to 
be easier to genetically manipulate; thus, several strains of transgenic Huntington’s disease 
model mice are readily available.
106
 Mice have the added benefit of being relatively inexpensive 
to purchase and house, compared to rats. Our work using mice in our study of Huntington’s 
disease is discussed in greater depth in Chapter 2. 
1.8.3 Zebrafish 
In this work, we develop a method for using FSCV to measure dopamine release in 
zebrafish whole mount retina. Zebrafish (danio rerio) present some unique advantages for use as 
a model organism, and yet, they are a relatively young animal model in research. Zebrafish were 
initially used as a model organism in the 1960s.
107
 Their relatively large, external embryos and 
fast life cycle make them an ideal model organism for studying development.
108-109
 The genome 
of zebrafish has been fully sequenced; thus, they are easily genetically manipulatable. As 
vertebrates, zebrafish have the added benefit of being relatively genetically similar to humans 
compared to invertebrate models such as fruit flies and c. elegans.
108
 Specifically, the functional 
architecture retina is well-conserved across vertebrates.
110
 In Chapter 4, our work developing a 
method to use zebrafish to study the retina is discussed further. 




1.9 USING FAST-SCAN CYCLIC VOLTAMMETRY TO MEASURE NEUROTRANSMITTER RELEASE 
IN ANIMAL MODELS 
One commonality throughout this work is the instrumentation used to measure 
neurotransmitter release in animal models. Figure 1.9.1 shows a block diagram of a typical 
instrumental setup for fast-scan cyclic voltammetry measurements of neurotransmitter release. 
On the computer, waveforms and stimulation patterns are input into the software. Through a 
breakout box and National Instruments cards, the digital signal from the software is converted to 
an analog signal and sent to the potentiostat and stimulating electrodes or LED setup. The 
potentiostat sends a waveform to the working electrode and receives current information from 
the working electrode, which it sends back to the computer.
 
Figure 1.9.1. Schematic showing a typical electrochemical setup for a fast-scan cyclic 
voltammetry experiment. 
1.9.1 Experimental setup 
In this work, brain slices and whole mount retinas are placed in a perfusion chamber, a 
schematic of which is shown in Figure 1.9.2. Artificial cerebrospinal fluid (aCSF) is perfused 
over the tissue in order to keep it functional throughout the course of the experiment. Artificial 
cerebrospinal fluid enters the chamber by gravity and is removed through vacuum suction. There 




is a reservoir where an Ag/AgCl reference electrode is placed. A microscope or stereoscope 
objective allows for visualization of the tissue and electrodes. Stimulating electrodes, fiber optic-
coupled LEDs for light stimulation, and carbon fiber microelectrodes can all be placed in the 
tissue using micromanipulators.  
 
Figure 1.9.2. Perfusion chamber. 
1.9.2 Fast-scan cyclic voltammetric measurements ex vivo 
Figure 1.9.3 (A) shows placement of stimulating electrodes and a carbon fiber 
microelectrode in a striatal brain slice obtained from a rat. As shown here, the working electrode 
is placed 100 µm deep in the striatal tissue directly between the two stimulating electrodes. 
Dopamine release is evoked electrically using the stimulating electrodes and measured at the 
working electrode. Electrical stimulation is necessary as the background subtraction required to 
obtain useful data using FSCV renders the technique incapable of detecting endogenous 
concentrations; rather, only changes in concentration can be quantified with FSCV. Serotonin 
release measurements were recorded similarly; the main differences were the waveform and 
stimulation paradigm, as well as the region of the brain. Later, retinal dopamine release 
measurements were collected using light stimulation; Figure 1.9.3 (B) shows a working electrode 




placed in adult zebrafish whole mount retina. To obtain concentration data, electrodes are 




Figure 1.9.3. (A) A carbon fiber microelectrode placed at a depth of 100 µm in rat striatal tissue, 
directly between stimulating electrodes. (B) A carbon fiber microelectrode placed at a depth of 
100 µm in adult zebrafish whole mount retina. 
1.10 SUMMARY OF FUTURE CHAPTERS 
In this work, fast-scan cyclic voltammetry at carbon fiber microelectrodes is used to 
measure neurotransmitter release in animal models. In Chapter 2, work is described in which 
serotonin release evoked by electrical stimulation was measured in Huntington’s disease model 
mice. Chapter 3 describes our work in which serotonin and dopamine release were measured in 
rats treated with chemotherapeutic agents. Chapter 4 describes the development and application 
of methods in which we measured dopamine release, evoked by stimulation with light, in whole 
mount zebrafish retinas. In the final chapter, conclusions and future directions are offered. 
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2 SEROTONIN RELEASE MEASUREMENTS IN HUNTINGTON’S DISEASE MODEL MICE 
2.1 ABSTRACT 
 Huntington’s disease is an autosomal dominant movement disorder associated with 
depression and other mood disorders. Serotonin has been implicated in depression. Despite this, 
serotonin has not been extensively measured in Huntington’s disease model rodents. In this 
work, we use fast-scan cyclic voltammetry to investigate how serotonin release in both the 
substantia nigra pars reticulata and the dorsal raphe nucleus, two brain regions densely 
innervated with serotonin-releasing terminals, are affected in Huntington’s disease model mice.  
2.2 INTRODUCTION 
Huntington’s disease is a fatal, progressive neurodegenerative movement disorder caused by 
a polymorphic trinucleotide CAG expansion on the htt gene, which encodes the protein 
huntingtin. The result of this expansion is an excess of polyglutamine repeats at the N-terminus 
leading to cellular toxicity
1
. Symptoms are typically onset between age 35-45 in humans, and 
death occurs 10-15 years afterward.
2
 Huntington’s disease affects about 30,000 Americans, and 
over 200,000 people in the United States are at risk. While its most obvious symptom is choreic 
movements, the tendency of patients with Huntington’s disease toward cognitive and mood 
disorders, as well as a marked increase in suicide, has been observed.
3
 Moreover, more recent 
studies have shown that patients with Huntington’s Disease display a higher prevalence of both 
depression and aggression compared to the general population. Interestingly, the onset of these 
systems often occurs before the onset of the motor deficits characteristic of Huntington’s disease 
and before patients are diagnosed; the prevalence of mood disorders has been found to be up to 
69%, with the prevalence of major depression 29%.
4-8
 Serotonin is thought to be involved in 




depression both in the general population and in patients with Huntington’s disease. Therefore, 
we wanted to determine whether serotonin release was affected in mice carrying a truncated 
version of the human Huntington gene. In this work, we use fast-scan cyclic voltammetry 
(FSCV) to measure serotonin release in rodent models of Huntington’s. 
2.2.1 Huntington’s disease 
Huntington’s chorea was first described by George Huntington (April 9, 1850 – March 3, 
1916) in 1872.
3
 Huntington was a physician in East Hampton on Long Island, and treated many 
patients in one family who presented with a similar phenotype.
9
 Huntington accurately described 
the adult-onset nature of the disease as well as the uncontrolled, choreic movements in his 
patients.
3
 Despite the newness of the field of genetics (Gregor Mendel had only just proposed his 
initial work on “genes” six years before Huntington’s paper in 1872),
10
 through careful study, 
Huntington was able to determine the inheritance pattern of the disease. As George Huntington 
initially described, Huntington’s Disease is a genetic disease passed down in an autosomal 
dominant pattern;
3
 the Huntington gene (htt), which encodes the protein huntingtin is located on 
the short arm of chromosome 4p16.3 in the Huntingtin gene.
1, 11
 The mutant htt gene includes a 
series of at least 36 CAG repeats, encoding a polyglutamine expansion on the huntingtin 
protein.
1, 11
 Figure 2.2.1 shows a schematic of a typical pedigree for a family carrying the 
Huntington gene. Some key features are the autosomal (i.e. not sex-linked) and dominant nature 
of the inheritance pattern. Since chromosome 4p16.3 is not a sex-linked gene, males and females 
are both equally likely to inherit the disease, and equally likely to pass it on to their children. The 
dominant nature of its inheritance means that just one copy of the mutant htt allele causes full-
blown Huntington's disease. Thus, in families with one parent with Huntington's, there is a 50% 
chance of passing the disease to each child, regardless of sex. 





Figure 2.2.1. Huntington’s disease is inherited in an autosomal dominant pattern. 
2.2.2 The three stages of Huntington’s disease 
Huntington’s disease can be broken down into three stages. In early stage Huntington’s 
disease, patients experience slight changes in motor function, coordination, and mood.
12
 At this 
stage, antidepressants are often prescribed to combat depression.
2
 In the middle stage of the 
disease, choreic movements, control over speech, and difficulty swallowing become more 
pronounced. In late stage Huntington’s disease, patients become unable to walk or speak, 
although their comprehension of surroundings does not diminish.
2, 11
 At this stage, patients are at 
risk for pneumonia due to lack of control over esophageal muscles, which is the number one 
cause of death in patients with Huntington’s disease.
2, 11
 
2.2.3 Psychiatric aspects of Huntington’s disease 
Huntington’s disease affects not just motor control, but also results in a variety of psychiatric 
symptoms. These include major depression,
13
 anxiety and irritability, apathy, and obsessive 
compulsive disorder.
7
 The prevalence of depressed mood in Huntington’s disease patients was 
found to range from 33% to 69% by different studies.
4-5, 14
 Suicide is the second leading cause of 
death in Huntington’s patients, and the prevalence of suicide in Huntington’s patients is four to 




eight-fold greater than in the general population.
15
 Similarly, anxiety ranged from 17-61% and 
irritability varied as well (35-73%).
5, 14, 16
 Obsessive compulsive disorder and psychosis were less 
common; both are estimated to have a prevalence of less than 20 percent.
6, 17
 
2.2.4 Prognosis and therapies for Huntington's patients 
Thus far, therapies for Huntington’s patients remain limited. There is no cure for Huntington’s 









 are given to ameliorate motor symptoms or delay their onset. In the case of the 
psychiatric aspects of the disease, selective serotonin reuptake inhibitors and antipsychotic drugs 
are given.
20, 22
 Recent advances in surgical options such as stem cell implantation have also 
shown promise in treating chorea in Huntington’s Disease patients.
23-24
 In addition to 







 diet, and exercise
8, 28-29
 regimens in patients with Huntington’s 
disease. 
2.2.5 A summary of current Huntington’s models  







 to create legions in the striatal brain 
tissue in rats, mimicking the pathology of Huntington’s Disease. These chemical models have a 
number of disadvantages, including the acute nature of the lesions. Furthermore, these models do 
not affect the other regions of the brain, where the Huntington protein is also expressed.
33
 
Several mutant rodent models of Huntington’s disease have been developed, including 
truncated N-terminal fragment models and full-length knock-in models. The truncated models 
typically have a fragment of the human HTT or a fragment of either rat or mouse HTT, including 




the R6/1 and R6/2 mouse models
34
 and the tgHD rat model.
35
 Several knock-in models 
containing the full-length human HTT also exist, as well as several transgenic models containing 
the full-length human HTT, such as the YAC-18, YAC-46, and YAC-72 mouse models.
33-34
 
2.2.6 R6/1 and R6/2 Huntington’s Disease models 
This work makes use of the R6/1 and R6/2 Huntington’s disease model mice, both of which 
are truncated fragment models. Both models contain 67 amino acids of the human HTT on IT15 
promoter. However, the R6/2 mouse contains 144 CAG repeats, whereas the R6/1 model only 
contains 116 repeats. In R6/2 mice, motor deficits can be observed as early as 5-6 weeks of age, 
while R6/1 model mice do not develop the overt motor phenotype until about 15 weeks of age. In 
mice displaying the overt motor phenotype, clasping, tremor, impaired gait, and choreic 




Serotonin has been thought to be involved in depression because of the usefulness of 
serotonin reuptake inhibitors in treating this condition.
36
 However, the initial monoamine 
hypothesis—that decreased levels of serotonin cause depression—has proven to be overly 
simplistic.
37
 A newer theory suggests that the interplay between external factors and genetics 
may be a better predictor of depression. In this area, much attention has been given to the 
serotonin transporter gene; a polymorphism on this gene can cause increase sensitivity to stress. 
Therefore, external stressors could be more likely to lead to depression in individuals carrying 
the polymorphism on the serotonin transporter gene.
38
  
In this work, serotonin release is measured in the dorsal raphe nucleus and the substantia 
nigra pars reticulata. The substantia nigra pars reticulata receives input from the dorsal raphe 




nucleus, where serotonin is synthesized. The dorsal raphe nucleus contains about 50% 
serotonergic neurons, and has the highest concentration of serotonergic neurons in the brain.
39
 
The substantia nigra pars reticulata has been found to be involved in motor control and 
movement disorders,
40-45




2.2.8 Previous work in Huntington's disease model rodents 
Alterations in the dopaminergic neurotransmission in multiple rodent models of Huntington’s 







 With respect to serotonin, less work has been done in Huntington’s disease 
models. However, inhibition of tryptophan hydroxylase, the rate-limiting enzyme in serotonin 
synthesis, was found in R6/2 model mice.
55
 Another study showed that both overall tissue levels 
of serotonin and serotonin 5HT2A receptor function were decreased in R6/2 model mice.
56
 
Furthermore, one study found altered serotonin receptor expression to be correlated with 
depressive behavior in R6/1 model mice,
57
 and another group successfully decreased depressive 
symptoms in R6/2 model mice with sertraline, a selective serotonin reuptake inhibitor.
58
 
2.2.9 This work 
  Fast-scan cyclic voltammetry is an electrochemical technique with great selectivity, as well 
as spatial and temporal resolution. This allows for measurements in real-time in live tissues and 
for determination of serotonin release measurements in response to stimuli. In this work, 
serotonin release measurements in the substantia nigra in R6/2 and R6/1 Huntington’s Disease 
model mice will be discussed.  




2.3 EXPERIMENTAL PROCEDURES 
2.3.1 Animals 
R6/2 and R6/1 Huntington’s Disease model mice, and their respective wild-type control mice 
were obtained from The Jackson Laboratory (Bar Harbor, ME). These mice were received at 
approximately 5 weeks old. For the initial study of serotonin release in the substantia nigra pars 
reticulata of R6/2 model mice, were aged to two experimental groups: 8 weeks and 12 weeks. 
For the study of serotonin release in the dorsal raphe of R6/2 model mice, mice were aged to 12 
weeks. For the study of serotonin release in the dorsal raphe of R6/1 model mice, mice were 
aged to 18 weeks. Mice were housed in the University of Kansas Animal Care Unit (ACU). The 
temperature and humidity were regulated (70 ± 2ºC, and 50% ± 25%, respectively). Mice were 
kept in a 12 h light/dark cycle, with unrestricted access to food and water.  
2.3.2 Brain slices  
Substantia nigra brain slices were prepared as previously described.
50-52
. Immediately 
following anesthetization, mice were decapitated and the brain was removed. The extracted brain 
was then placed in an ice bath of artificial cerebrospinal fluid (aCSF) containing 95% 
O2/5%CO2, 126 mM NaCl, 22 mM HEPES, 1.6 mM NaH2PO4, 2.5 mM KCl, 25 mM NaHCO3, 
2.4 mM CaCl2, 1.2 mM MgCl2, and 11 mM D-glucose, adjusted to a pH of 7.4. After removal of 
the cerebellum with a razorblade, the brain was superglued with all purpose Krazy glue (Elmer’s 
Products, Westerville, OH, USA) to the slice platform and supported by a 1 cm
3
 block of agarose 
gel for slicing. The slice platform was then submerged in an ice bath of aCSF. A Leica VT1000 
S vibrating-blade microtome (Leica Microsystems, Nussloch, Germany) was used to obtain 
coronal slices of 300 um thickness.  Slices were placed in a perfusion chamber. Slices were 




perfused with aCSF at a flow rate of 1 mL/min and kept at a temperature of 34° C. An 
equilibration time of 60 min was allowed before measurements were obtained.  
2.3.3 Drug 
In order to confirm the measurement of serotonin, fluoxetine, a selective serotonin reuptake 
inhibitor, was used. Fluoxetine was obtained from Sigma-Aldrich, St. Louis, MO, USA. Prior to 
drug application, a stable serotonin signal was established. Fluoxetine was dissolved in a stock 
solution of water. Then, the stock was added to the aCSF perfusing over the slice at a 
concentration of 2 µM.  
2.3.4 Electrode fabrication 
Carbon-fiber microelectrodes were fabricated as previously described.
50-52, 59
 Glass 
capillaries (1.2 mm outer diameter, 4 inch-long A-M Systems, Inc. Carlsborg, WA, USA) were 
threaded with 7 µm diameter carbon fibers (Goodfellow, Huntingdon, UK). The capillaries were 
then heated and pulled with a PE-22 heated coil puller (Narishige Int. USA, East Meadow, NY),. 
The carbon fiber was cut to a length of 30 µm from the glass tip. Electrode tips were sealed with 
epoxy (EPON resin 815 C, EPIKURE 3234 curing agent, Miller-Stephenson, Danbury, CT, 
USA). Electrodes were cured for 1 h at 100 ºC. 
Prior to serotonin measurements, the electrodes were coated with Nafion by electrodeposition 
using a method adapted from Robinson et al.
60
 The electrode tips were soaked in isopropyl 
alcohol for 30 min. A 0.5 M potassium acetate solution was used to backfill electrodes in order 
to allow the carbon fiber to conduct to a silver wire inserted in the back of the electrode. The 
electrode was then lowered such that the tip was immersed in Nafion solution (Nafion 
perfluorinated ion-exchange resin, 5 wt. % solution in a mixture of lower aliphatic alcohols and 




water, Sigma-Aldrich, St. Louis, MO, USA). A constant potential of +1.0 V vs. Ag/AgCl was 
then applied for 30 s, and the electrode was cured for 10 min at 70 ºC. Electrodes were stored for 
up to 1 week until use. 
2.3.5 Electrochemistry 
Electrodes were calibrated before and after experiments by collecting measurements for 
known concentrations of serotonin in a flow cell. Stimulation electrodes were fabricated by 
gluing two stainless steel electrodes (A-M Systems Inc., Carlsborg, WA, USA) and controlling 
the distance between them (200 um) with heat shrink (3 M Electronics, Austin, TX). 
Electrochemical measurements were obtained using a Dagan Chem-Clamp Voltammetric 
Amperometric Amplifier (Dagan Corporation, Minneapolis, MN, USA), which was interfaced 
with a computer by a breakout box. Software written by M. L. A. V. Heien and R. M. Wightman 
(Department of Chemistry, University of North Carolina, Chapel Hill, NC, USA) was used to 
analyze stimulated serotonin release plots. 
 Carbon fiber microelectrodes were inserted 100 µm into brain slices, directly between the 
two stimulating electrodes in the substantia nigra. Serotonin release was then evoked by the 
application of 20 biphasic electrical pulses (4 ms long, 350 µA current) at 50 Hz. In order to 
detect serotonin, a modified triangular waveform of +0.2 V to +1.0 V down to -0.1 V and back 
up to +0.2 V at a scan rate of 800 V/s was used.
61
 A Ag/AgCl reference electrode was used. Peak 
currents after stimulation were background-subtracted, and cyclic voltammograms characteristic 
of serotonin were observed.  




2.3.6 Statistical analyses 
 For the R6/2 SNr study, statistical analyses were performed using a two-way ANOVA in 
GraphPad Prism 6.0 (p < 0.005). Values were expressed as averages ± SEM; n = 6 to 9 mice. For 
the R6/2 dorsal raphe study, statistical analysis were performed using a t-test; n = 4 mice, p < 
0.05. For the R6/1 dorsal raphe study, statistical analysis was performed using a t-test; n = 5 
mice. 
2.4 RESULTS AND DISCUSSION 
2.4.1 Confirmation of serotonin release 
Serotonin release in brain slices was confirmed by addition of fluoxetine, a selective serotonin 
reuptake inhibitor. Fluoxetine (10 µM) was added to the aCSF perfusate. Figure 2.4.1 shows 
representative data collected in the substantia nigra pars reticulata confirming serotonin release. 
On the left, a representative current vs. time plot, serotonin cyclic voltammogram, and color plot 
is shown for a file obtained before the addition of any drug to the perfusate. On the right is a 
current vs. time plot, cyclic voltammogram, and color plot obtained 15 min after the addition of 
10 µM fluoxetine to the perfusate. In these color plots, which consist of a series of cyclic 
voltammograms unfolded, rotated, and stacked over time, potential is plotted on the y-axis, time 
is on the x-axis, and current is encoded in false color representing the z-axis.  Horizontal dashed 
lines on the color plots indicate the potential from which the representative current vs. time plots 
were extracted, while vertical dashed lines indicate the times from which the representative 
cyclic voltammograms were extracted. Here, serotonin release was stimulated by 20 biphasic 4-
ms 350µA electrical pulses at 50 Hz. Electrical stimulation occurred at 5 s. Immediately 
following electrical stimulation, a peak occurs on the representative current vs. time plots; the 




extracted cyclic voltammogram at this time is characteristic of serotonin. After adding 
fluoxetine, a selective serotonin reuptake inhibitor, serotonin reuptake was inhibited, as 
evidenced by the current not returning to baseline and the increase in maximum current due to 
serotonin release.  
 
 
Figure 2.4.1. Serotonin release is confirmed by perfusing 10 µM fluoxetine over the brain slice. 
Left: current vs. time plot, representative serotonin cyclic voltammogram, and color plot 
obtained from substantia nigra pars reticulata brain slice before adding any drug to the perfusate. 
Right: current vs. time plot, serotonin cyclic voltammogram, and color plot after addition of 10 
µM fluoxetine to the perfusate. Horizontal dashed lines represent potential from which each 
current vs. time plot was extracted; vertical dashed lines represent time from which each 
respective cyclic voltammogram was extracted.  




2.4.2 Serotonin release is diminished in the substantia nigra pars reticulata in an age-
dependent manner 
For this study, serotonin release was measured in the substantia nigra, pars reticulata (SNr) in 
R6/2 model mice. A carbon fiber microelectrode was placed between two stimulating electrodes 
in a 350-µm thick brain slice containing SNr tissue at a depth of 100-µm. Serotonin release was 
evoked by applying 20 biphasic 350-µA electrical pulses at 50 Hz at the stimulating electrodes. 
Figure 2.4.2A shows representative data from both wild-type and R6/2 mice. 
First, measurements were recorded in 8-week old R6/2 model mice and their age-matched 
wild-type controls. Serotonin release was diminished to 41.0±5.0% of the controls (two-way 
ANOVA; N=5 R6/2 and 5 wild-type; Sidak’s multiple comparisons test, p<0.01). Considering 
the progressive nature of Huntington’s disease, we sought to determine whether there was an 
age-dependent effect. Therefore, we obtained serotonin release measurements in 12-week old 
R6/2 model mice and their age matched controls. Our results, depicted in Figure 2.4.2B, show 
that serotonin release was further diminished at 12 weeks to 15.9±2.5% of the controls (two-way 
ANOVA; N=5 R6/2 and 5 wild-type; Sidak’s multiple comparisons test, p<0.001), suggesting an 
age-dependent effect. Age was determined to have a significant effect on serotonin release (two-
way ANOVA, p<0.05). 
 





Figure 2.4.2. (A) Representative color plots, current traces, and CVs collected from the 
substantia nigra, pars reticulata in wild-type and R6/2 model mice, respectively. Horizontal 
dashed lines indicate the potential from which each current vs. time plot was extracted; vertical 
dashed lines show the time from which each cyclic voltammogram was obtained. Representative 
cyclic voltammograms are characteristic of serotonin, confirming serotonin release. (B) Average 
concentrations of maximum serotonin released shown at 8 and 12 weeks for both R6/2 and wild-
type controls. Error bars are SEM. N = 5 R6/2 and 5 wild-type mice for both 8- and 12-week 
groups; two-way ANOVA, p<0.01 for 8 weeks, p<0.001 for 12 weeks. 






2.4.3 Serotonin release is decreased in both the dorsal raphe and substantia nigra regions 
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Figure 2.4.3. Average concentrations of maximum serotonin release in the dorsal raphe of WT 
and R6/2 mice. Mice were 12 weeks old. (p<0.05, paired t-test, N = 5 WT and 5 R^/2 mice) 
After determining that serotonin release was decreased in the SNr of R6/2 model mice, we 
decided to perform further experiments to discern whether release was also decreased in the 
dorsal raphe (DR). Figure 2.4.3 shows the results of those experiments; serotonin release was 
found to be decreased by 28.2±7.9% in 12-week old R6/2 model mice compared to the age-
matched wild-type controls. These data suggest that release impairments may be generalized 
throughout the entire brain. Furthermore, as the dorsal raphe is implicated in mood disorders, 
serotonin release dysfunction could play some role in depression and anxiety in Huntington’s 
disease. 
 




2.4.4 Decreased serotonin release in the dorsal raphe is conserved across multiple mouse 
models 
 Upon finding that serotonin release is decreased in multiple regions of the brain in R6/2 
model mice, we performed further studies to determine if this effect was conserved across 
multiple models of Huntington’s disease. Thus, we obtained measurements of serotonin release 
using the same methods in the DR of a different mouse model, the R6/1 Huntington’s Disease 
model. Figure 2.4.3 shows that in 18-week old R6/1 model mice, serotonin release was decreased 
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Figure 2.4.3. Average concentrations of serotonin released in the dorsal raphe of WT and R6/1 
mice. These data were collected from current vs. time plots. Mice were 12 weeks old. (p<0.05, 
paired t test, N = 5 WT and 5 R6/1)  
To our knowledge, this is the first time serotonin release has be measured in Huntington’s 
disease model mice using fast-scan cyclic voltammetry. After confirming serotonin release, we 




were able to quantify serotonin release in the substantia nigra pars reticulata and the dorsal raphe 
of R6/2 model mice, as well as the dorsal raphe of R6/1 model mice.  
Previous work shows that dopamine release in brain slices is impaired in R6/2 and R6/1 
model mice.
50-51
 Our work builds on this and suggests that release impairments may be persistent 
throughout the entire brain. Moreover, it shows that release impairments throughout the brain are 
conserved across different mouse models of Huntington’s disease. Furthermore, our results show 
that neurotransmitter release throughout the brain is affected in an age-dependent manner. 
There is evidence that depressive symptoms in Huntington’s disease model mice could be 
related to serotonin dysfunction.
56-58, 62
 Our work here shows that serotonin release is diminished 
in the dorsal raphe of both R6/1 and R6/2 model mice. As this brain region is thought to be 
involved in mood disorders such as depression,
46
 a decrease in serotonin release in the dorsal 
raphe could be a contributing factor to depression in Huntington’s disease. 
Interestingly, serotonin release was decreased in two different regions of the brain in R6/2 
model mice. In the past, alterations in dopamine release have been found in the striatum.
50-52
 
Since release in multiple neurotransmitter systems is attenuated, it is possible that this decrease 
in release occurs due to similar mechanisms.  
2.5 CONCLUSIONS 
Taken together, this work suggests a global decrease in release and raises the possibility of a 
common mechanism. Additionally, a robust effect is conserved across multiple models. 
Furthermore, it implies that regions of the brain other than the striatum ought to be given more 
attention with respect to Huntington’s disease, given the roles of the DR and SNr in both mood 
and motor control.  
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3 NEUROTRANSMITTER RELEASE AND BEHAVIORAL MEASUREMENTS IN CHEMOTHERAPY-
TREATED RATS 
3.1 ABSTRACT 
Chemobrain is a condition affecting as many of 75% of patients who have received 
chemotherapy treatments for cancer. As cancer survival rates improve and the population of 
cancer survivors grows, it is becoming more important to consider the quality of life of this 
population. In this work, we investigate the effect of two chemotherapeutic agents, 5-fluorouracil 
(5-FU) and carboplatin, on neurotransmitter release in rat brain. We also investigate a potential 
therapy, a heat shock protein inhibitor developed at the University of Kansas by Dr. Brian 
Blagg's group, KU-32. In addition to this, we have collaborated with Dr. David Jarmolowicz's 
group to study the effect of these treatments on cognitive behavior. We found that in rats treated 
with 5-FU, dopamine release was impaired, but was recovered after a recovery time of three 
weeks. 5-FU-treated rats also showed cognitive behavior deficits; their performance on a 
paradigm testing attention was decreased. Interestingly, KU-32 treatments were able to prevent 
this effect. We also found that in rats treated with carboplatin, serotonin release was decreased in 
the substantia nigra pars reticulata and the dorsal raphe nucleus. Our collaborator found that 
carboplatin-treated rats showed decreased performance on paradigms testing both inhibition and 
spatial learning. This work suggests that multiple neurotransmitter systems are affected across 
multiple chemotherapeutic drugs, and that these neurotransmitter measurements can be 
correlated with cognitive deficits. Furthermore, work suggest a potential therapy in KU-32. 






As outcomes for cancer patients continue to improve, new challenges have arisen. Over 
the course of the past half-century, cancer mortality rates have decreased globally.
1
 Figure 
3.2.1A shows the decline in cancer mortality with the United States and Canada since 1975. A 
growing population of cancer survivors creates a growing need to improve the quality of life of 
cancer survivors post-chemotherapy. In 2013, depending on the stage of diagnosis, 55-82% of 
breast cancer patients received chemotherapy as part of their treatment,
2
 and yet, the toxicity of 
chemotherapeutic agents can cause a slew of complications for patients, including severe nausea 
and vomiting, anemia, infertility, hair loss, fatigue, depression, and cognitive impairment.
3
 
Figure 3.2.1B shows the increase in interest in chemotherapy-induced cognitive impairment 
within the scientific community. The focus of this work is chemotherapy-induced cognitive 
impairment, or “chemobrain.”  





Figure 3.2.1. (A) The cancer mortality rates in the United States and Canada in the past 40 years. 
(World Health Organization, Department of Information, Evidence and Research, mortality 
database (accessed on July 20 2017)).
1
 (B) Publications on cognitive impairment and 
chemotherapy within the same time frame (Search performed July 20 2017). 
 Chemobrain has been described clinically as a decline in executive function, including 
memory, learning, and attention span. Patients describe their symptoms as forgetfulness and lack 
of focus.
4
 Furthermore, patients with chemobrain also experience an increased prevalence of 




 Estimates vary, but chemobrain may affect 
as many as many as 75% of patients receiving chemotherapy treatment. Due to the implications 




of quality of life in a growing population, it is important to study the underlying neurological 




5-FU is a chemotherapy drug that has been used to treat several cancers including 
gastrointestinal cancer,
6










5-FU acts as a thymidylate synthase inhibitor. Thymidilate synthase is an enzyme that 
normally methylates deoxyuridine monophosphate, forming thymidine monophosphate. 
Thymidine monophosphate is essential for DNA replication; therefore, 5-FU halts DNA 





Figure 3.2.2. Structures of 5-FU and dUMP. 
There is mixed evidence regarding 5-FU and chemobrain. Andreis et al. found a lack of 
chemobrain effect with oxaliplatin, 5-FU, and leucovorin combination treatment in colon cancer 
patients.
13
 On the other hand, Mustafa et al. found that 5-FU affected spatial and working 




memory and neurons in the adult rat hippocampus,
14
 and Fardell et al. found that 5-FU and 
oxaliplatin treatment impaired novel object recognition and spatial reference memory.
15
 
Moreover, 5-FU has been shown to cross the blood brain barrier and cause destruction of 
myelin.
16
 In this work, we investigate the effect of 5-FU treatment on dopamine release in the 
striatum, combined with behavioral measurements of attention and inhibition. 
3.2.3 KU-32 
KU-32 was used in this work as a potential therapy for chemobrain and was given to rats 
via oral gavage along with their 5-FU injections. KU-32 is a novel novobiocin-based heat shock 
protein 90 inhibitor developed at The University of Kansas by Dr. Brian Blagg’s group
17
 and has 
shown promise as a therapy for diabetic neuropathy.
18
 KU-32 works by binding to heat shock 
protein 90, releasing heat shock factor 1, and inducing the heat shock response; heat shock 
proteins maintain protein homeostasis through proper folding.
19
 Figure 3.2.3 shows the structure 
of KU-32. 
 
Figure 3.2.3. KU-32. 
 As KU-32 has shown promise in treating degeneration in the peripheral nervous system, 
it could prove effective in treating toxicity in the central nervous system as well. Here, we 




investigate the potential of KU-32 as a therapy for chemobrain by co-administering KU-32 with 
5-FU treatment. 
3.2.4 Carboplatin 










triple negative breast cancer.
24
 In cancer patients receiving carboplatin as a single agent (i.e. not 
in combination with other drugs), carboplatin is typically administered by intravenous infusion 
once every 21 days for about six months.
25
 It works by covalently binding to DNA, forming 
reactive platinum complexes, and causing cell death.
26-27
 Figure 3.2.4 shows the chemical 
structure of carboplatin.  
 
Figure 3.2.4. Carboplatin. 
 In humans, carboplatin has been found to cause cognitive impairment in elderly 
patients;
28
 a combination of cyclophosphamide, methotrexate, and 5-FU has also been shown to 
cause cognitive impairment.
29
 We wanted to investigate further the effect of carboplatin on 
working memory and to combine behavioral measurements with neurotransmitter release 
measurements. In this work, rats were treated with carboplatin by i.v. tail vein injection to study 
these effects. 




3.2.5 Neurotransmitter release measurements in this work 
Previous work has been done to elucidate mechanisms of chemobrain and investigate 
possible therapies.
30-31
 For instance, Sara Thomas used microdialysis to measure glutamate and 
GABA in rats treated with 5-FU, carboplatin, or doxorubicin.
32
 Biosensors have also been used 
to examine dopamine uptake in mice treated with doxorubicin.
33
 In our lab, Kaplan et al. used 
fast-scan cyclic voltammetry to measure dopamine release and uptake.
34
 Fast-scan cyclic 
voltammetry (FSCV) at carbon fiber microelectrodes is an electrochemical technique that allows 
measurements of neurotransmitter release to be obtained with low limits of detection and high 
spatial and temporal resolution.  In this work, we use FSCV to investigate whether 5-FU affects 
dopamine release and whether changes in dopamine release caused by chemotherapy treatment 
correspond with cognitive deficits measured by behavioral paradigms for attention shifting, 
inhibition, and spatial learning. We then determine whether KU-32 could be a possible therapy 
for chemobrain. We also investigated whether dopamine release recovers in rats treated with 5-
FU are given time to recover from treatments. Finally, we determine whether serotonin release is 
affected by carboplatin treatments and correlate those measurements to cognitive behavioral 
measurements. 
3.3 MATERIALS AND METHODS 
3.3.1 Animals 
All animal procedures were approved by the Institutional Animal Care and Use Committee at 
the University of Kansas. Wistar rats were obtained from Charles River (Raleigh, NC) and 
housed and fed in pairs in the Animal Care Unit at the University of Kansas. Rats were 
maintained on 22-h food restriction. on a 24-hour light-dark cycle. Rats who underwent 




behavioral testing were kept on 22-hour food restriction. During 1-h behavioral experiment 
sessions, rats received food pellets (45 mg, Bio-Serv, Frenchtwon, NJ) followed by ad libitum 
food for the remainder of the 2-h access period. Cages were kept on a 12-h:12-h light-dark cycle, 
with experimental sessions occurring in the light phase. 
3.3.2 Treatments 
3.3.2.1 5-FU and KU-32 study 
Wistar rats were treated with either a 20 mg/kg dose of 5-FU or an equivalent volume of 
saline vehicle once per week for two weeks via i.v. tail vein injection. Half of the rats receiving 
5-FU also received KU-32 via oral gavage. KU-32 oral gavage treatments were administered 
immediately following 5-FU injections. 
3.3.2.2 5-FU recovery study 
Wistar rats were treated with either a 20 mg/kg dose of 5-FU or an equivalent volume of 
saline vehicle once per week for two weeks via i.v. tail vein injection. Half of the rats receiving 
5FU treatments were euthanized for electrochemical measurements one week following the final 
injection, and the other half were euthanized three weeks after receiving their final injection. 
Vehicle-treated rats were euthanized one week after receiving their final injections. 
3.3.2.3 Carboplatin study 
Male Wistar rats received one injection (i.v., tail vein) of carboplatin once a week for 
four consecutive weeks. For this round of treatment, there were two experimental groups 
consisting of treatment with 0.9% biological saline or a 20 mg/kg dose of pharmaceutical grade 
carboplatin (10 mg/mL, Hospira, Inc.). Both dosage and treatment regimen were chosen to 
mimic clinical dosing regimens and to allow the drug effects to stabilize. 




3.3.3 Brain Slices 
Rats under isoflurane anesthesia were decapitated and the brain was removed. Next, 350-µm 
thick slices containing the striatum were obtained using a vibratome. Striatal slices were placed 
on a perfusion chamber, and artificial cerebrospinal fluid (aCSF) was perfused over the slices. 
The aCSF (126 mM NaCl, 22 mM HEPES, 1.6 mM NaH2PO4, 2.5 mM KCl, 25 mM NaHCO3, 
2.4 mM CaCl2, 1.2 mM MgCl2, and 11 mM D-glucose, adjusted to a pH of 7.4) was oxygenated 
with 95/5% O2/CO2 and kept at physiological temperature using a heater (manufacturer) in order 
to keep the slices viable for the duration of the experiment. Once placed on the perfusion 
chamber, slices were allowed to equilibrate for 1 hour prior to electrochemical measurements. 
3.3.4 Carbon fiber microelectrode fabrication 
FSCV at carbon fiber microelectrodes was used to measure neurotransmitter release. 
Electrodes were fabricated in-house as previously described.
35
 First, a 7-µm in diameter carbon 
fiber (Goodfellow, Huntingdon, UK) was threaded through a glass capillary (0.6 mm I.d., 1.2 
mm o.d., 4-in long, A-M systems, Inc. Carlsborg, WA, USA) using a vacuum pump. Then, the 
glass capillary was pulled to a point encasing the carbon fiber using a heated-coil puller. Next, 
the carbon fiber tip was cut to 30 µm in length using a scalpel. The electrodes were dipped in 
epoxy resin (815 C, EPIKURE 3234 curing agent, Miller-Stephenson, Danbury, CT, USA). 
Excess epoxy was removed by dipping electrodes in toluene. Finally, electrodes were cured in an 
oven for 1 hour at 100°C.  
In addition to these steps, electrodes used for serotonin release measurements were 
coated with Nafion, a cation exchange polymer, in order to increase sensitivity to serotonin and 
decrease sensitivity to 5-hydroxyindoleacetic acid, a serotonin metabolite that could interfere 
with serotonin measurements. Electrodes were soaked in isopropyl alcohol to remove any 




impurities from the electrode surface. Then, they were backfilled with a 0.5 M potassium acetate 
solution to make a connection with the silver wire in the back of the electrode and the carbon 
fiber. Electrodes were manipulated so they were immersed in Nafion (Nafion perfluorinated ion-
exchange resin, 5 wt. % solution in a mixture of lower aliphatic alcohols and water, Sigma-
Aldrich, St. Louis, MO, USA), and Nafion was electrodeposited on the carbon fiber surface by 
applying a constant potential of 1.0V for 30 seconds. After electrodeposition, electrodes were 
dried in an oven at 70°C for 10 minutes and stored in a cool, dry place. Electrodes with Nafion 
coatings were used within 1 week in order to avoid any issues with Nafion degradation. 
3.3.5 Dopamine measurements in the striatum of 5-FU-treated rats 
After equilibration, dopamine release measurements were made by FSCV. Four 
measurements were made in each of four quadrants (dorsal lateral, dorsal medial, ventral lateral, 
and ventral medial) of the striatum, to account for the heterogeneity of the striatum. Dopamine 
release was evoked using a single biphasic 4-ms 350-µA pulse applied at the stimulating 
electrodes. FSCV measurements were made using carbon fiber microelectrodes. Microelectrodes 
were 7-µm in diameter and cut to 30-µm long. A waveform of -0.4V up to +1.0V and back down 
to a holding potential of -0.4V was applied at 300 V/s. Characteristic dopamine cyclic 
voltammograms were obtained, and the corresponding current vs. time plots were compared to 
flow cell calibrations in order to obtain concentration data. Measurements were made vs. a 
Ag/AgCl reference electrode. 
3.3.6 Serotonin measurements in the dorsal raphe of carboplatin-treated rats 
Serotonin measurements were collected similarly to dopamine measurements. However, 
a different electrical stimulation paradigm was used: 20 4-ms biphasic 350 µA pulses at a 




frequency of 50 Hz. A serotonin-optimized waveform was applied at the working electrode: 0.2 
V scanning up to 1.0 V, down to –0.1 V, and back up to 0.2 V at a scan rate of 800 V/s. 
3.3.7 Behavioral experiments 
3.3.7.1 Apparatus 
 Behavioral sessions were conducted in standard MedPC operant chambers (30.5 cm 
long, 24.1 cm wide, 29.2 cm high; Med Associates, Inc., St. Albans, VT) illuminated by 28-V 
houselights centered on the back wall (26.7 cm from the floor). Centered on the front wall, 1 cm 
above the floor grid was a pellet receptacle (3 cm × 4 cm) into which a pellet dispenser dispensed 
pellets. On the curved, rear wall were five side-by-side nose-poke access openings (2.54 cm × 
2.54 cm), each illuminated by a cue light and featuring infrared response recording. Nose-poke 
openings were 2.54 cm apart and 2 cm from the floor. Chambers were housed in sound 
attenuating cabinets with white noise fans. 
3.3.7.2 5-choice serial reaction time paradigm 
Sessions occurred 6 days a week at approximately the same time each day and lasted for 1 
h.  A nose poke into the pellet receptacle was required to trigger the start of the task. Then, 5 s 
after the initial nose poke into the receptacle, a stimulus light turned on above the active target. 
Triggering the active target within 5 s of the light turning on resulted in the delivery of one 45 
mg pellet.  
 




3.3.7.3 Differential reinforcement of low rates paradigm 
The rats were 5 months old at the beginning of the experiment. Behavioral testing was 
performed a minimum of six out of every seven days, at approximately the same time each day, 
for four weeks. There was no pre-training performed because rats had previous experience with 
schedules of reinforcement. All rats experienced 12–14 sessions prior to the experimental phase 
and twice received saline intravenous (i.v.) and saline oral gavage administrations immediately 
following behavioral sessions. For the experimental phase, rats were randomly placed into one of 
two groups (KU32 + 5-FU or SAL + 5FU). The experimental phase for each rat began following 
the first administration of 5-FU and KU32/SAL. A second administration occurred one week 
later. Behavioral data were collected up to one week following the second administration 
Rats began behavioral sessions on differential reinforcement of low-rate 20-s schedules 
of reinforcement (DRL20). Food pellets were contingent on successive nose-poke responses in 
the center nose-poke opening (NP3) with inter-response times (IRTs) greater than or equal to 20 
s. An NP3 response with an IRT less than 20-s reset the interval, such that the IRT between the 
resetting response and the subsequent response needed to be 20 s in order to earn a reinforcer. 
Nose-poke responses on the other four nose-poke openings were recorded but did not reset the 
interval or earn reinforcement. DRL20 schedules moved to DRL40 schedules prior to the 
experimental phase for all but two rats. 
3.3.7.4 Spatial learning paradigm 
Sessions occurred 6 days a week at approximately the same time each day and ended either 
after the rats earned 100 reinforcers or 1 h had passed. At the beginning of each session, the 
house light and the stimulus lights in each of the five nose poke receptacles were turned on. In 
each session, one of the five nose pokes was made active. Specifically, triggering the infrared 




sensor in that receptacle resulted in a brief tone (0.1 s), the extinguishing of all nose poke cue 
lights for 5 s, the lighting of the pellet receptacle, and the delivery of one 45 mg pellet. 
Responding on the other four nose poke receptacles was recorded but did not result in any 
differential consequences. The target nose poke remained constant for each session, with the 
order of conditions varying quasi-randomly. 
3.4 RESULTS AND DISCUSSION 
3.4.1 Dopamine release impairment in rats treated with 5-FU 







 and mood control.
42-44
 In 
chemobrain, multiple studies have shown that dopamine may be involved.
45-49
 Therefore, we 
chose to investigate the potential role of dopamine release in 5-FU-treated rats. 
The striatum was divided into four quadrants in each coronal slice, and electrically 
stimulated dopamine release was quantified in the quadrants. Measurements were taken in the 
four quadrants to account for the heterogeneity of innervation in the striatum.
50
 Figure 3.4.1A 
shows the division of a coronal brain slice into dorsal lateral (DL), dorsal medial (DM), ventral 
medial (VM), and ventral lateral (VL) quadrants. 
 Electrically stimulated DA release in each quadrant of the striatum was measured with 
FSCV in 350 µm-thick coronal brain slices. Here, a single, biphasic 4-ms 350 µA electrical pulse 
was applied at the stimulating electrodes at 5 seconds. In response to electrical stimulation, 
dopamine release and uptake was observed. Figure 3.4.1B shows representative color plots, 
current vs time, and cyclic voltammograms for vehicle- and 5-FU-treated rats, respectively. The 
cyclic voltammograms are characteristic of dopamine, confirming dopamine release. The color 




plots consist of cyclic voltammograms that have been unfolded, rotated, and stacked over time. 
Current is represented in false color on the z-axis. No other faradaic currents are apparent, 








Figure 3.4.1. (A) Four quadrants of the striatum in coronal slices. DL = dorsal lateral, DM = 
dorsal medial, VM = ventral medial, and VL = ventral lateral. (B) Representative data collected 
in the striatum of vehicle- and 5-FU-treated rats, respectively. 
Figure 3.4.2 shows the overall results for dopamine release in 5-FU treated rats and the 
saline vehicle-treated controls. Wistar rats were treated with either a 20 mg/kg dose of 5-FU via 
i.v. tail vein injection or the equivalent volume of saline vehicle. A two-way ANOVA revealed 
no significant interaction between treatment group and region of the striatum (p=0.94), so there 
did not appear to be a region-dependent difference in effect of 5-FU. Therefore, dopamine 
release was averaged across all four quadrants; in rats treated with 20 mg/kg 5-FU, dopamine 
release in the striatum was decreased to 63.3±9.5% of the vehicle-treated controls (two-way 
ANOVA, p<0.05, N = 5 vehicle and 9 5-FU treated rats). Chemobrain symptom include learning 
and memory deficits, as well as lack of attention span and inhibition;
46, 51-54
 dopamine has been 
shown to influence each of these.
36-39, 41, 44, 55
 Thus, it is possible that dopamine release 
attenuation throughout the striatum in response to 5-FU treatment could be a contributing factor 
in chemobrain.  




Figure 3.4.2. Dopamine release is impaired in 5-FU treated rats compared to saline-treated 
controls. (n = 5; two-way ANOVA, p < 0.05) 
3.4.2 Dopamine release recovery study 
Clinical studies have shown mixed results on the lasting effects of chemobrain. Some 
find that chemobrain symptoms are transient. Whitney et al. found that in patients who received 
cisplatin for non-small cell lung cancer, 62% of patients in the study showed cognitive decline 
after treatments, but the effect dissipated after 7 months.
56
 Others have found a longer-lasting 
effect. Wefel et al. found both acute and long-term cognitive effects in breast cancer patients 
receiving 5-fluorouracil, doxorubicin, and cyclophosphamide.
57
 Therefore, we wanted to 
investigate further whether 5-FU-induced depression of dopamine release in the striatum was a 
transient or lasting effect.  
Figure 3.4.3 shows the overall dopamine release data for the 5-FU recovery study. For 
this study, rats were given either one week or three weeks to recover from 20 mg/kg 5-FU 
treatments (i.v. tail vein) before dopamine release measurements were made. Our results show 
that dopamine release impairment was not significantly different in different quadrants of the 
striatum; therefore, release measurements were averaged across all four quadrants. Dopamine 




release was found to be significantly impaired in the one-week recovery group (50.4±8.7% of 
vehicle-treated control), and the three week recovery group (66.0±9.7% of vehicle-treated 
control). These results suggest that dopamine release impairment is a lasting effect in rats treated 
with 5-FU. Thus, lasting cognitive changes in patients treated with 5-FU may be related to 






















































































































Figure 3.4.3. Striatal dopamine release in 5-FU-treated rats was attenuated in both 5-FU groups: 
1 week and 3 week recovery. (N = 4 vehicle, 5 5-FU 1 week recovery, and 6 5-FU 3 week 
recovery rats; *p < 0.05, ***p < 0.001, two-way ANOVA Tukey’s multiple comparisons test) 




3.4.3 5-FU impairs performance on 5-choice serial reaction time test 
Figure 3.4.4 shows the performance of rats treated with 20 mg/kg 5-FU compared to saline 
vehicle-treated controls on the 5-choice serial reaction time paradigm. After just one injection of 
5-FU, the percent change from baseline in number of reinforcers earned was significantly lower 
than rats who received saline injections. The effect remained after a second injection. 
 
Figure 3.4.4. Rats treated with 5-FU (20 mg/kg, i.v. tail vein injection) showed a significantly 
lower % change from baseline compared to saline-treated controls. (n = 10 5-FU rats and 6 saline 
rats) 
3.4.4 KU-32 treatment prevents 5-FU-induced inhibition deficits 
Figure 3.4.5 shows mean reinforcers earned across D1, D7, and D14 for rats in the 5-FU + KU32 
group (squares) and 5-FU + Saline (circles). A Two-way ANOVA revealed significant main 
effects of group (F = 10.5, p = 0.003) and non-significant effects for time point (F = 0.286, p = 
0.75). A significant interaction effect (F = 3.92, p = 0.029), however, was found between group 
and time point. Post hoc comparisons revealed that the 5-FU + KU32 group earned  significantly 




more reinforcers than the 5-FU + Saline group at the second (p = 0.033) and third (p = 0.031) 
treatment (i.e. three time points). 
 
Figure 3.4.5.  Mean number of reinforcers earned (y-axis) for the 5-FU + Saline group (circles) 
and 5-FU + KU32 group (squares) across D1, D7, and D14 (x-axis). 
The top panel of Figure 3.4.6 shows mean reinforcers earned divided by total NP3 
responses across D1, D7, D14 for rats in the 5-FU + KU32 (squares) and 5-FU + Saline (circles) 
groups. There were significant main effects of group (F = 13.3, p = 0.001), time point (F = 3.5, 
p = 0.046), and the interaction of group and time point (F = 5.9, p = 0.008). Post hoc 
comparisons revealed that those rats in the KU32 + 5-FU group were significantly more efficient 
in their reinforcers/total NP3 responses than those in the Saline + 5-FU group at D14 
(p = 0.0001). Within groups, there were no significant differences across time points within the 
5-FU group, however, those rats in the 5-FU + KU32 group were significantly more efficient in 
their reinforcers/NP3 responding at D14 compared to D1 (p = 0.002) or D7 (p = 0.002). 





Figure 3.4.6. Mean reinforcers earned divided by total NP3 responses (y-axis) across D1, D7, 
and D14 (x-axis) for rats in the 5-FU + KU32 (squares) and 5-FU + Saline (circles) groups. 
Figure 3.4.7 shows mean nose-poke responses (y-axis) per nose-poke target (x-axis) for 
both 5-FU + Saline (open squares) and 5-FU + KU32 rats (open circles) for D1 (top panel), D7 
(middle panel), and D14 (bottommost panel). Gaussian curves are fit to each group's mean 
responses across each target at a given time point (i.e. D1, D7, and D14). To determine level 
differences in responses between the two groups, two-way ANOVAs comparing mean responses 
across nose-poke targets were used. Significant differences were only observed between the 
groups on D14 such that the 5-FU + Saline group exhibited more responses than the 5-
FU + KU32 group. A post hoc comparison revealed that the only significant difference in mean 
responses between the groups on D14 was at NP3 (p = 0.006). An index of the Gaussian gradient 
(FWHM) was derived for each group at each time point. A two-way ANOVA revealed non-
significant findings for group (p = 0.23) and time point (p = 0.26) suggesting no differences in 
spatial discrimination across the two groups. 





Figure 3.4.7. Top, middle, and bottom panels represent D1, D7, and D14 respectively. Mean 
responses (y-axis) per nose-poke target (axis) are plotted for 5-FU + KU32 rats (squares and 
dotted gradient) and 5-FU + Saline (circles and non-dotted gradient). 
3.4.5 Serotonin release in carboplatin-treated rats 
To examine further the mechanism underlying chemobrain, we also measured the 
stimulated release of 5-HT within the dorsal raphe nucleus. Serotonin plays a vital role in 




cognition, including memory and learning processes
58-59
 and synaptic plasticity.
60
 Furthermore, 
the interplay between 5-HT and other neurotransmitter systems, including DA, has been 
shown.
61-62
 Due to the specific involvement in cognition and interplay with the DA system, we 
chose to study electrically stimulated 5-HT release in the dorsal raphe nucleus by FSCV. Five 
measurements were taken within the dorsal raphe from each brain slice and averaged. 
Representative data from the 0 and 20 mg/kg carboplatin treatment groups are shown in Figure 
3.4.8A. The representative cyclic voltammograms indicate that the analyte measured is 5-HT. As 
shown in Figure 3.4.8B, the peak concentration of serotonin released following electrical 
stimulation was significantly diminished in 20 mg/kg carboplatin-treated rats compared to saline-
treated rats (45 ± 9% of saline control, n = 5 carboplatin-treated and 5 vehicle-treated rats, p < 
0.05, unpaired t test). Our results suggest that impaired 5-HT release may contribute to the 
cognitive deficits experienced by patients who have undergone chemotherapy treatment. Taken 
together with DA release impairments, these results indicate that chemotherapy may induce a 
general effect upon the mechanism of neurotransmitter release. Thus, it is likely that the release 
of other neurotransmitters, such as glutamate and GABA, is impaired; consequently, the impact 
of these deficits on cognitive function should also be considered. 





Figure 3.4.8. Serotonin release in the dorsal raphe nucleus is attenuated in carboplatin-treated 
rats. 
3.4.6 Carboplatin treatment causes decreased performance on a spatial learning 
paradigm 
To test for carboplatin related deficits in spatial learning, rats were evaluated on a spatial 
learning paradigm in which five response options (i.e., nose-pokes detected by infrared beam) 
were presented in a horizontal row. When the rats poked their noses to a target preselected by the 
investigator, a food reward was delivered. This paradigm consistently results in Gaussian 
response distributions centered on the target location, with steeper Gaussian functions indicating 
more robust spatial learning.
63
 Figure 3.4.9 shows the spread of responses to nontarget nose 
pokes (A), responses at the nontarget positions, 2 and 4 (B), overall rates of nose pokes (C), and 
rats’ weights during the testing phase (D). As can be seen, the responses to nontarget nose poke 
locations (expressed as a proportion of the rate of nose pokes on the target location) fit well into 
a Gaussian function for rats treated with saline (r
2
= 0.99) and 20 mg/kg carboplatin (r 2 = 0.96). 




The parameters for these Gaussian functions significantly differed between groups (F[2,64] = 
4.339, p < 0.05). Moreover, t test of responding at individual targets found that the proportion of 
target responses on nose poke location 2 (t[60] = 2.0651, p < 0.05) and 4 (t[60] = 2.41287, p < 
0.05) differed significantly between carboplatin and vehicle-treated rats (Figure 3.4.9B). No 
significant differences were obtained for overall rate of nose pokes (Figure 3.4.9C; p = 0.65) or 
rats’ weights during the testing phase (Figure 3.4.9D; p = 0.29). Consistent with the 
neurochemical data, a treatment course of carboplatin resulted in altered cognitive function. 
Here, carboplatin resulted in small but significant alterations in spatial learning/memory that 
resulted in increased responding to nontarget nose poke locations on a spatial learning paradigm. 
The degree of cognitive impairment observed following carboplatin treatment is consistent with 
chemotherapy patients’ symptoms, which often present as subtle impairments in parameters such 
as learning, concentration, reasoning, and executive function.
64
 An important aspect of these 
cognitive measurements is that the overall rates of responding did not significantly differ 
between carboplatin- and vehicle-treated groups (p > 0.05). Additionally, rats did not lose weight 
during or after treatment, suggesting that food consumption and general feeling of well-being 
was not impacted. Taken together, these results strongly suggest that the decreased responding of 
carboplatin-treated rats on locations 2 and 4 was not due merely to a detriment of overall health, 
but rather to the more specific effect of cognitive impairment. 





Figure 3.4.9. Spatial learning measurements obtained using operant conditioning chambers. The 
spread of responses (A) is expressed as a proportion of the rates of nose pokes at each location 
and is fit to a Gaussian function for both the vehicle-treated (r 2 = 0.99) and carboplatin-treated 
(r 2 = 0.96) rats (F [2,64] = 4.339, p < 0.05, n = 7, vehicle versus carboplatin). The responses at 
the nontarget positions, 2 and 4 (B), overall rates of nose pokes (C), and rats’ weights during the 
testing phase (D) are also shown (*p < 0.05, n = 7 rats per group). 
3.5 CONCLUSIONS 
The particular mechanisms underlying neurotransmitter release impairments following 
chemotherapeutic treatment have not yet been identified. However, it is possible that multiple 
factors contribute, including influences by other neurotransmitters and neuromodulators that 
have become dysregulated due to carboplatin treatment, damage to proteins that mediate 
exocytosis, and morphological degradation of neuronal terminals. In future studies, it will be 




important to address these issues to identify specific cellular mechanisms that contribute to 
release impairment. Additionally, it will be critical to design behavioral and neurochemical 
experiments so that we can determine the relevance of neurotransmitter release alterations in 
specific brain regions, such as the striatum and dorsal raphe nucleus, to cognitive ability. 
In summary, our 5-choice serial reaction time, differential reinforcement of low rates, and 
spatial learning paradigm results indicate a decrease in cognitive performance; thus, it is possible 
that diminished neurotransmitter release capability negatively impacts cognitive ability. 
Collectively, these findings (1) suggest neurotransmitter release impairment as a possible 
mechanism of cognitive dysfunction in patients treated with chemotherapeutic agents and (2) 
support the need for more refined behavioral and neurochemical analyses to elucidate how 
release is impaired and which neurotransmitter systems are affected. 
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4 NEUROTRANSMITTER RELEASE MEASUREMENTS IN ADULT ZEBRAFISH WHOLE MOUNT 
RETINA 
4.1 ABSTRACT 
As the population in the United States ages, the prevalence of retinal disease has increased. 
However, the mechanisms of retinal disease are not well-understood. Here, we attempt to 
develop a new model for studying neurotransmitter release in adult zebrafish whole mount retina 
using fast-scan cyclic voltammetry at carbon fiber microelectrodes, a sensitive electrochemical 
technique that allows for high spatial and temporal resolution. In this work, we were able to 
confirm Ca
2+
-mediated neurotransmitter release in response to light stimulation with a 470-nm 
wavelength fiber-optic-coupled LED system by titrating Ca
2+
 into the artificial cerebrospinal 
fluid; when Ca
2+
 was titrated into the solution, neurotransmitter release appeared. We also 
conducted experiments perfusing alpha-methyl-p-tyrosine, a tyrosine hydroxylase inhibitor, and 
quinpirole, a dopamine D2 receptor agonist. Our alpha-methyl-p-tyrosine experiments showed 
that dopamine release was diminished by 84.6±9.3% compared to the maximum signal obtained, 
supporting our hypothesis that the neurotransmitter release was a catecholamine. Our quinpirole 
experiments showed that dopamine release was decreased to 38.3±15.2% of the signal, 
suggesting that the catecholamine released was dopamine. Overall, dopamine release in the 
retina was found to be 0.27±.05 µM. 
4.2 INTRODUCTION 
As the population both in the United States and worldwide ages, diseases of the retina have 
become more important to study. Retinal degeneration will affect over 5 percent of the 
population at some time during their lives and is the leading cause of blindness in the developed 






 Age-related macular degeneration (AMD) affects more than 8,000,000 Americans, with 
the prevalence of AMD projected to increase by 50% by 2020.
3
 Since AMD is primarily a 
degeneration of cones,
4
 it is important that a model organism used to study AMD should have a 
cone-rich retina. Therefore, zebrafish are an ideal model organism in which to study the retina, 
because their retinas are very rich in cones compared to other models such as rodents.
5
  
Much work has been done mapping the retina with immunohistochemistry,
6-10
 and 
Hirasawa et al. have measured dopamine and GABA released from amacrine cells cultured from 
mouse retina using a combination of patch-clamp and amperometry.
11-15
 However, to our 
knowledge, real-time measurements of neurotransmitter release have not been recorded in 
whole-mount retinas. In this work, we have developed a method to use fast-scan cyclic 
voltammetry (FSCV) to measure real-time dopamine release in adult zebrafish whole-mount 
retinas. 
4.2.1 Relevant ocular anatomy 
This work is focused on development of a method to study neurotransmitter release in 
whole-mount retinas. Therefore, it is important to understand the role the retina plays in sight. 
Light enters the eye through the cornea, which is the transparent covering of the front of the eye, 
and passes through the aqueous anterior chamber.
16-18
 The iris, which is the colored part of the 
eye, acts as a shutter on the pupil, the aperture through which light passes.
16-20
 Then, light 
focused by the lens passes through the vitreous humor and forms an image on the retina, which 
transmits the image to the brain through the optic nerve.
16-18, 21
 Figure 4.2.1 shows a schematic 
diagram of a human eye. 
 





Fig 4.2.1. A schematic of the human eye. (Figure adapted from Kels et al.
17
 with permission. 
©Elsevier 2015) 
As this work is concerned with the retina, it is important to understand the relevant retinal 
anatomy. Figure 4.2.2 shows a schematic of the layered structure of the retina, which is 
conserved across vertebrates. The outer nuclear level consists of photoreceptors, which can be 
divided into rods and cones; rods and cones are responsible for dim-light vision and color vision, 
respectively. Both types of photoreceptors are glutamatergic and synapse with bipolar cells at the 
outer plexiform layer; communication between bipolar cells and photoreceptors is modulated by 
horizontal cells. Bipolar cells can be either rod or cone-bipolar cells and receive input from those 
respective photoreceptor types. Additionally, bipolar cells can be divided into ON- and OFF-
bipolar cells. ON bipolar cells depolarize in response to increments of light, whereas OFF bipolar 
cells hyperpolarize in response to increments of light. 





Figure 4.2.2. A schematic diagram of the layered structure of the vertebrate retina. ONL = Outer 
nuclear layer, OPL = Outer plexiform layer, INL = Inner nuclear layer, IPL = Inner plexiform 
layer (containing both OFF and ON sublamina), GCL = ganglion cell layer, R = rods, C = cones, 
HC = Horizontal cells, BC = Bipolar cells, AC = Amacrine cells, RGC = Retinal ganglion cells. 
Figure reproduced with permission from Hoon et al. ©Elsevier 2014.
22
 
 In this work, we sought to measure dopamine release in the retina. Contini and Raviola 
showed that dopaminergic amacrine cells in the retina synapse with cell bodies of AII amacrine 
cells.
23
 Furthermore, Hirasawa et al. used electrophysiology to determine that dopamine and 
GABA were coreleased from dopaminergic amacrine cells and that dopamine acted on both 
nearby and distant retinal cells by volume transmission.
12
  
4.2.2 Zebrafish as a model organism 
In this work, we develop a method for using FSCV to measure dopamine release in 
zebrafish whole mount retina. Zebrafish (danio rerio) present some unique advantages for use as 
a model organism, and yet, they are a relatively young animal model in research. Zebrafish were 




initially used as a model organism in the 1960s.
24
 Their relatively large, external embryos and 
fast life cycle make them an ideal model organism for studying development.
25-26
 The genome of 
zebrafish has been fully sequenced; thus, they are easily genetically manipulatable. As 
vertebrates, zebrafish have the added benefit of being relatively genetically similar to humans 
compared to invertebrate models such as fruit flies and c. elegans.
25
 Specifically, the functional 
architecture retina is well-conserved across vertebrates.
22
 However, there are a few differences 
between the structure of zebrafish retinas and human retinas, which we will discuss here. 
Humans have three major classes of cones with sensitivity to red, green, and blue wavelengths, 
respectively; zebrafish, on the other hand, have a fourth class of cones which are sensitive to 
ultraviolet wavelengths.
22
 Moreover, there are differences between humans and zebrafish in 
cellular distribution and connectivity. Zebrafish have more types of horizontal cells, and their 
cone bipolar cells are more interconnected than human bipolar cells;
22
 zebrafish retina is also less 
densely populated with ganglion cells.
27
 Furthermore, the zebrafish retina is thinner than human 
retina (180 µm and 280 µm, respectively).
28-29
 Nevertheless, the zebrafish retina is a better model 
of the human retina compared to other animals such as mice, as mice have rod-dominated vision 
instead of cone-dominant vision (i.e., zebrafish see in color while rodents do not).
30
 This is 




FSCV is a sensitive electrochemical technique with high temporal and spatial resolution 
when coupled with carbon fiber microelectrodes. In this work, we develop a method to study 
real-time neurotransmitter release in adult zebrafish whole mount retina at carbon fiber 
microelectrodes.  






All animal procedures were approved by the University of Kansas Institutional Animal 
Care and Use Committee. Zebrafish were housed in the Molecular Probes Core of the Center for 
Molecular Analysis of Disease Pathways at the University of Kansas. 
4.3.2 Retina removal 
 Zebrafish retinas were removed using a procedure adapted from Zou et al.
10
 Briefly, 
zebrafish were euthanized by rapid chilling and decapitated. Zebrafish retina removal was 
performed under a dissection stereoscope (Leica Microsystem, Bannockburn, IL). The zebrafish 
head was immobilized on agarose for dissection using a 19-gauge syringe needle (Figure 
4.3.1A). Two incisions were made on the top of the eye using SuperFine Vannas Scissors (8cm, 
curved, 3mm blades) and the lens was removed using Dumont #5 forceps (Figure 4.3.1B). The 
eye was removed and the optic nerve was severed using the same forceps and scissors (Figure 
4.3.1 C). Finally, the sclera and whole mount retina were separated using the same forceps 
(Figure 4.3.1 D). 
 





Figure 4.3.1. Retina removal. (A) After decapitation, the zebrafish head is immobilized on 
agarose using a 19-gauge syringe needle. (B) Small incisions in the front of the eye allow for 
removal of the lens. (C) The eye cup is removed and optic nerve severed. (D) The removed 
sclera, retina, and lens. 
4.3.3 Electrochemistry 
 Once removed, retinas were placed in a perfusion chamber, and artificial cerebrospinal 
fluid (aCSF) was perfused over the retina. The aCSF was composed of 126 mM NaCl, 22 mM 
HEPES, 1.6 mM NaH2PO4, 2.5 mM KCl, 25 mM NaHCO3, 2.4 mM CaCl2, 1.2 mM MgCl2, and 
11 mM D-glucose, adjusted to a pH of 7.4. aCSF was maintained at a temperature of 27°C, the 
same temperature as the zebrafish tank system water, and oxygenated using 95/5% O2/CO2. The 
perfusion chamber was protected from light and retinas were equilibrated in darkness for 1-h 
prior to data collection. To stimulate neurotransmitter release, a 2-s, 850 mA light pulse was 
applied using a 470-nm fiber optic coupled LED (Thorlabs, Newton, New Jersey). 




4.3.4 Pharmacological studies 
Dopamine, α-methyl-p-tyrosine methyl ester (AMPT), nomifensine, and quinpirole, were 
purchased from Sigma-Aldrich (St. Louis, MO). 
4.4 RESULTS & DISCUSSION 
4.4.1 Initial neurotransmitter release data collected in the retina 
Initially, we sought to measure dopamine release in adult zebrafish whole mount retinas. 
Figure 4.4.1 shows the very first representative data we obtained. A retina was removed from an 
adult zebrafish and placed in a perfusion chamber, which was perfused with oxygenated aCSF at 
27°C. After placement on the perfusion chamber, the retina was equilibrated in darkness for one 
hour. These data were obtained by placing a carbon fiber microelectrode 100 µm deep in the 
center of the retina and stimulating the retina with white light. Figure 4.4.1 shows (A) placement 
of a carbon fiber microelectrode in zebrafish retina tissue and (B) placement of a fiber optic 
coupled LED such that light stimulus shines directly on the retina tissue. Here, a 2-s 850-mA 








Figure 4.4.1. (A) A carbon fiber microelectrode is place 100 µm deep in the center of a zebrafish 
whole mount retina. (B) A fiber-optic coupled 470-nm LED is shone directly onto the retina in 
order to stimulate neurotransmitter release. 
 
Figure 4.4.2 shows the initial representative data collected in the retina for an experiment in 
which nomifensine, a dopamine reuptake inhibitor, was perfused over the retina. The left panel 
shows a color plot, representative current vs time plot, and representative cyclic voltammogram 
before the addition of drug. The color plot consists of a series of cyclic voltammograms (i.e. 
current vs potential plots) unfolded, rotated, and stacked over time. These plots show potential 
on the y-axis, time on the x-axis, and current is encoded in false color, representing the z-axis. 
Horizontal dashed lines represent the potential at which current vs time plots were extracted, 
while vertical dashed lines show the time from which representative cyclic voltammograms were 
extracted. A 2-s light stimulation was applied 5-s into data collection. At 5 s, a current peak 
occurs on the current vs time plot, indicating stimulated neurotransmitter release. The peak 
returns to baseline, indicating reuptake into the cell. Since representative cyclic voltammogram 
resembled a dopamine cyclic voltammogram, we perfused 2 µM nomifensine over the retina to 
determine whether the neurotransmitter released was dopamine. The middle panel shows a 
representative color plot 20 min after addition of nomifensine to the perfusate. These data show 
that after addition of nomifensine, the current measured did not return to baseline as it did before 
the addition of drug, suggesting that reuptake was inhibited and that the neurotransmitter 
released could be dopamine. The panel on the right shows representative data collected 20 min 
after washing nomifensine out of the perfusate. Here, the current returned to slightly below the 




pre-drug level, suggesting that the inhibition of uptake observed in the center panel was due to 
nomifensine addition.  
 
Figure 4.4.2. Initial experiments revealed potential dopamine release in response to light 
stimulation. Right: pre-drug; center: 20 min after adding 2 µM nomifensine to perfusate; right: 
20 min after washing nomifensine out of perfusate. 
4.4.2 Light-stimulated neurotransmitter release is Ca2+-dependent 
After our initial experiments, we decided to characterize further the release we observed 
by determining whether it was calcium-dependent. Exocytotic neurotransmitter release depends 
on the availability of calcium in cells.
31
 Here, we performed our experiment in the same way as 
before, but without adding calcium to the aCSF. The carbon fiber microelectrode was placed 100 
µm deep, directly in the center of the retina and not moved for the duration of the experiment. 
The retina was stimulated with a 2-s, 850 mA, 470-nm light pulse. Figure 4.4.3 shows (A) 
representative current vs time plots and (B) overall results for this set of experiments. The 
representative current vs time plots show that before addition of calcium, there was no 
significant current obtained in response to the light stimulus. After titration of calcium to 100% 
of the normal calcium concentration in aCSF (2.5 mM), release occurred in response to the light 




stimulus. The amount of neurotransmitter released increased by 13.6-fold compared to the pre-
calcium amount (p<0.05, one-tailed paired t test, N = 4 retinas). These results suggest calcium-
dependent exocytosis is occurring in response to light stimulation. 
 
Figure 4.4.3. (A) Representative data; calcium-dependent neurotransmitter release in the retina. 
(B) Average maximum concentrations of dopamine released before and after addition of calcium 
to the aCSF (*p<0.05, one-tailed paired t test, N = 4 retinas.) 
4.4.3 Alpha-methyl-p-tyrosine causes disappearance of light-stimulated neurotransmitter 
release 
In order to determine whether any part of the signal was attributable to dopamine or 
norepinephrine, a pharmacological experiment was performed using the drug α-methyl-p-
tyrosine (AMPT). Tyrosine hydroxylase (TH) is the rate-limiting enzyme in 
catecholaminesynthesis, and AMPT blocks TH. Therefore, one would expect a disappearance of 
catecholamine release after AMPT blocks synthesis. After a stable electrochemical signal was 
obtained, AMPT (50 µM) was added to the perfusate. Release was evoked every 10 minutes 




using the same light stimulation paradigm. After 180 minutes, the signal diminished by 
84.6±9.3% (p<0.05, one-way ANOVA, Sidak’s multiple comparisons test, N = 4 retinas). After 
the signal reached a minimum, AMPT was washed out of the perfusate, and the retina was 
allowed to recover for one hour before another stimulation was applied. After one hour, when 
light stimulation was applied again, the signal returned to 58.9±18.0% of the maximum. There 
was no significant difference between the signal obtained after washout and the original 
maximum dopamine release. Figure 4.4.4 shows (A) a scheme depicting the action of AMPT 
inhibiting dopamine synthesis, (B) representative current vs time plots collected at various times 
after perfusion of AMPT over the retina, and (C) overall average maximum dopamine release 
concentrations before AMPT, 180 min after addition of AMPT, and 1 h after washout of AMPT.  
Our results suggest that the species released in response to light stimulation depends on the 
activity of AMPT. Therefore, the signal could be attributable to dopamine or norepinephrine. As 
previously mentioned, more work has been done measuring dopamine release
11-12, 15
 than 
norepinephrine release in retinal cells. However, N. N. Osborne found by autoradiography that 
norepinephrine might be released in very small amounts in the inner nuclear layer of bovine 
retina.
32
 Therefore, future studies are necessary to determine which catecholamine is responsible 
for the signal obtained here. 





Figure 4.4.4. (A) A scheme depicting the inhibition of catecholamine synthesis, by AMPT. (B) 
Representative current vs time plots collected in zebrafish whole mount retina 0, 60, and 180 min 
after addition of AMPT, and 60 min after AMPT washout. (C) Average release pre-AMPT, 180 
min after AMPT, and 60 min after AMPT washout (one-way ANOVA, Sidak’s multiple 
comparisons test, *p<0.05, N = 4 retinas). 
4.4.4 Quinpirole causes a significant decrease in the maximum concentration of dopamine 
released 
To determine whether the signal we observed was due to dopamine or norepinephrine, we 
performed experiments using quinpirole, a selective D2 receptor agonist.
33
 D2 dopamine 
autoreceptors are present in the retinal inner nuclear layer.
34
 When an agonist binds a D2 
autoreceptor, it activates the a negative  feedback loop, inhibiting release of dopamine from 






 Therefore, a decrease in release due to addition of quinpirole would support the 
conclusion that the observed signal is dopamine. Here, 10 µM quinpirole was added to the aCSF 
perfusate. Figure 4.4.5 shows (A) representative current vs time plots before and after the 
addition of quinpirole, and after washing quinpirole out of the perfusate and (B) average 
maximum dopamine release concentrations before adding quinpirole, after adding quinpirole, 
and after a washout of the drug. After the addition of quinpirole, the dopamine signal decreased 
to 38.3±15.2% of the original signal (p<0.05, one-way ANOVA, Sidak’s multiple comparisons 
test, N = 4 retinas). When quinpirole was washed out, the signal recovered to 78.5±25.3% of the 
original signal; there was no significant difference between the signal obtained after the washout 
and the original signal. These results suggest that at least some portion of the signal is due to 
release of dopamine in response to light stimulation. 
 
Figure 4.4.5. (A) Representative current vs time plots collected in adult zebrafish whole mount 
retina before the addition of 20 µM quinpirole, 20 min after the addition of quinpirole, and 20 
min after a quinpirole washout. (B) Average dopamine release data for pre-quinpirole, after 
quinpirole, and after a quinpirole washout (one-way ANOVA, Sidak’s multiple comparisons test, 
*p<0.05, N = 4 retinas). 





Overall, data pooled from multiple retinas showed that dopamine release was 0.23 ± 0.05 µM. 
To our knowledge, these measurements are the first of their kind; therefore, we are unable to 
compare these data to previous results. However, Shin et al. found that dopamine release in 




We have shown that dopamine release can be measured using FSCV in adult zebrafish whole 
mount retina. To our knowledge, these measurements are the first of their kind. The only other 
similar study by Witkovsky et al. found steady-state vitreal concentrations of dopamine in 
clawed frog eyes using a combination of FSCV and HPLC.
37
 However, for their FSCV 
measurements, they did not stimulate release but simply lowered the working electrode into the 
eyecup during data collection to obtain a measurement of dopamine within the vitreous humor of 
the eye compared to the buffer in the perfusion chamber. Moreover, they did not perform any 
pharmacological studies to confirm dopamine release. We took their approach a step further by 
measuring light-stimulated dopamine release in the retina. In summary, our work represents an 
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5 CONCLUSIONS AND FUTURE DIRECTIONS 
In this work, we have used electroanalytical techniques to address biological problems in 
multiple model organisms. Specifically, we applied FSCV measurements in Huntington’s disease 
model mice, rats treated with chemotherapy, and zebrafish retinas. Here, we discuss the overall 
conclusions from this work as well as future directions. 
5.1 SEROTONIN MEASUREMENTS IN HUNTINGTON’S DISEASE MODEL MICE 
In this work, we aimed to understand further the underlying neurochemical changes in 
Huntington’s disease (HD). Therefore, we measured serotonin release in the substantia nigra and 
dorsal raphe nucleus of R6/2 HD model mice using fast scan cyclic voltammetry. We also 
measured serotonin release in the dorsal raphe nucleus of R6/1 model mice. Our results showed 
that serotonin release was impaired in both the substantia nigra, pars reticulata and dorsal raphe 
of R6/2 model mice. Additionally, we found that serotonin release in the substantia nigra, pars 
reticulata was progressively impaired as R6/2 mice aged. Our results in R6/1 model mice showed 
that serotonin release was impaired in the dorsal raphe. This work demonstrates that 
neurotransmitter release throughout the brain could be affected by HD and represents a key step 
in understanding the neurochemistry of HD.  
5.2 SEROTONIN AND DOPAMINE RELEASE MEASUREMENTS IN CHEMOTHERAPY-TREATED 
RATS 
Another aim of this work was to understand better the underlying neurochemical 
abnormalities of post-chemotherapy cognitive impairment, or “chemobrain.” These alterations 
may contribute to cognitive changes including memory loss, attention deficits, and mood 
disorders such as depression.  




Carboplatin is a platinum-based chemotherapeutic agent that works by binding DNA, 
forming reactive platinum complexes, and causing apoptosis.
1
 Previously, Kaplan et al. found 
that dopamine release was impaired in the striatum in Wistar rats that were treated with 
carboplatin.
2
 Here, we wanted to determine whether neurotransmitter release was generalized 
throughout the brain. Furthermore, since symptoms of chemobrain include depression and other 
mood disorders, we decided to measure serotonin release due to serotonin's involvement 
involvement in mood control.  
In this work, rats were treated with either 25 mg/kg carboplatin (i.v. tail vein) or an 
equivalent volume of saline vehicle once per week for four weeks. One week after the final 
injection, we used FSCV to measure serotonin release in brain slices obtained from the dorsal 
raphe, which is a serotonin-rich region of the brain known to be involved in mood. We also 
collaborated with Dr. David Jarmolowicz's lab to measure spatial learning in the same rats 
throughout the course of the chemotherapeutic treatment regimen. Together, our results showed 
that rats treated with carboplatin had impairments in both dopamine and serotonin release, and 
these neurochemical changes corresponded with impairments in spatial learning and memory. 
Next, we sought to determine whether dopamine release impairments occur after treatment 
with other chemotherapeutic agents. Here, we treated rats with the chemotherapy drug 5-
fluorouracil (5-FU), which works by blocking thymidylate synthase, an enzyme required for 
DNA synthesis, thereby causing apoptosis.
3
  One week after the final treatments, dopamine 
release was measured in striatal brain slices. In addition to our dopamine release measurements, 
our collaborator measured inhibition throughout the chemotherapeutic treatments. We found that 
dopamine release was impaired throughout the striatum.  




We also wanted to investigate a potential therapy for chemobrain, so we co-administered 
KU-32, a heat shock protein inhibitor that has shown promise in treating neuropathy developed 
by Dr. Brian Blagg's group.
4
 Rats received one injection of either 5-FU (20 mg/kg, i.v. tail vein) 
or an equivalent volume of saline vehicle, once per week for two weeks. Half of the rats who 
received 5-FU were also treated with KU-32 (25 mg/kg, oral gavage). Our collaborator used a 5-
choice serial reaction time test to demonstrate that KU-32 prevented 5-FU-induced impairment 
of attention shifting. Another student in our lab, Anuranga Bandara, measured peroxide 
transients in striatal brain slices obtained from these rats; preliminary data showed that KU-32 
normalized hydrogen peroxide transients. However, more work needs to be done to characterize 
peroxide transients further. 
 
Figure 5.2.1. KU-32 normalized hydrogen peroxide transients. One-way ANOVA, p<0.05, N = 
3 to 5 rats. 
There is some disagreement among clinicians as to whether chemobrain is a transient or 
long-lasting disorder.
5-6
 Therefore, we wanted to determine whether the changes in dopamine 


















longer than one week. Here, we repeated the 5-FU treatment regimen (20 mg/kg i.v. tail vein, 
once per week for two weeks). Then, we measured dopamine release in striatal brain slices at 
two different times after the final injection: one week and three weeks. Our results demonstrated 
that dopamine release impairments did not recover after a slightly prolonged recovery time. In 
the future, it will be important to measure neurotransmitter release at even longer recovery times. 
This work is useful because it provides a framework for future studies. Recently, students in 
the Johnson and Jarmolowicz groups have been training to perform in vivo FSCV measurements 
in combination with behavioral measurements. This will allow our groups to combine in vivo 
measurements with simultaneous cognitive behavior measurements in the future. Furthermore, in 
vivo measurements have the advantage of allowing researchers to collect data at multiple time 
points, which will allow our groups to track the cognitive behavior and neurotransmitter release 
measurements of individual rats over time. 
5.3 DEVELOPMENT OF A METHOD TO MEASURE DOPAMINE RELEASE WITH FSCV IN 
ZEBRAFISH WHOLE MOUNT RETINA 
As the population in the United States with age-related macular degeneration (AMD) is set 
to increase to 20 million by 2020,
7
 it has become increasingly important to study the retina. Here, 
we developed a method to use FSCV to measure dopamine release in adult zebrafish whole 
mount retinas. Preliminary data suggested that dopamine release could be occurring in response 
to stimulation with a 470-nm LED, so we chose to investigate further. Our results showed that 
the signal was dependent on calcium, suggesting that exocytotic release was occurring. Then, we 
wanted to determine whether the neurotransmitter released was a catecholamine, so we perfused 
α-methyl-p-tyrosine (AMPT), a tyrosine hydroxylase inhibitor, over the retina. These 
experiments revealed that the signal disappeared after 180 min of perfusing AMPT and returned 




60 min after washing AMPT out of the perfusate. Finally, we sought to determine whether the 
catecholamine signal could be attributed to dopamine, which has been shown to be present in the 
retina. Therefore, we performed experiments in which we added quinpirole, a selective D2 
dopamine receptor agonist, to the perfusate. After 20 min of perfusing quinpirole over the retina, 
the signal was significantly decreased. Thus, we concluded that at least a portion of the signal 
was due to dopamine release. 
This work represents a crucial step toward understanding neurotransmission in the whole 
retina. Previously published work has drawn a link between dopamine receptor activation and the 
ability of retinal pigmented epithelium cells to break down waste products, which is a crucial 
function for retinal health.
8-9
 Therefore, a longer term goal of this work is to identify alteration in 
dopamine release and uptake properties in the retina, especially in genetically altered zebrafish, 
to identify possible mechanisms of AMD. Keeping the retina intact instead of measuring 
neurotransmitter release in retina cells creates many possibilities. For example, we will be able to 
measure the effects of different retinal cell types on each other. In the future, we will be able to 
use the methods developed here to study the effects of retinal disease on neurotransmitter release 
in whole mount retinas. Here, we have developed a very promising tool for understanding 
mechanisms of retinal disease, such as AMD. 
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